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The enteric nervous system
The enteric nervous system is a collection of neurons that constitutes the “brain of the gut” and can
function independently of the central nervous system1. It is a multifunctional system that controls
motility2,3, exocrine and endocrine secretions4, and microcirculation5 of the gastrointestinal tract; it is
also involved in regulating immune and inflammatory processes6.
The enteric nervous system is primarily derived from cells of the vagal segment that arise from the
medulla oblongata passing to the oesophagus, heart, bronchi, lungs, stomach and subsequently move
caudally to populate the entire gastrointestinal tract7.The vagus fibres form a single nerve on each side
of the oesophagus. It has been estimated that 80% of the fibers in the vagal trunk are afferent fibers8.
Parasympathetic innervation of the pancreas is provided by the vagus nerves.The splanchnic nerves
of the pancreas contain the sympathetic fibers and arise from the fifth to the ninth thoracic ganglia.
Both the sympathetic and parasympathetic fibers pass the celiac and superior mesenteric plexus before
they reach the pancreas. The adrenergic preganglionic fibers end in these plexuses, whereas the
parasympathetics pass uninterrupted and end in the intrinsic pancreatic ganglia. From here the adren-
ergic postganglionic fibers form a perivascular network with the pancreatico-duodenal and splenic
vessels9,10.The parasympathetic postganglionic fibers are distributed to acini, ducts and smooth mus-
cles11.
The innervation of the gallbladder can be seperated into an intrinsic and an extrinsic nervous sys-
tem12.The intrinsic nerve system of the gallbladder is suggested to be under cholinergic and peptider-
gic control.The extrinsic neural control is mainly mediated through parasympathetic and sympathe-
tic nerve fibers8,13. Inhibition of the vagal-cholinergic system with atropine or truncal vagotomy results
in an increase in fasting gallbladder volume and an impaired gallbladder contraction during the
cephalic and gastric phase of digestion14,15,16,17,18.The gallbladder smooth muscle contains both alpha and
beta-adrenergic receptors8,19. Since the gallbladder contains only a small number of alpha-adrenergic
receptors, under normal circumstances, adrenergic stimulation results in relaxation of the gallbladder
through activation of the more numerous inhibitory beta-receptors8.The existence of a non-adrener-
gic, non-cholinergic, possibly VIP-ergic nerve system has been postulated8,20.
The vagal-cholinergic system is of utmost importance during the cephalic and gastric phases of
postprandial gallbladder contraction. During the intestinal phase, hormonal factors e.g. cholecys-
tokinin (CCK) or motilin play a major role but the cholinergic system seems to modulate the gall-
bladder respons to these hormones at the end-organ level21,22,23.
Pancreatic polypeptide
The discovery of avian pancreatic polypeptide (PP) was an accidental event associated with studies
that involved the isolation of chicken insulin24.Chance et al., isolated PP from pancreatic extracts from
several mammalian species25. Additional studies demonstrated that avian and bovine PP contain 36-
amino acid residues with a molecular weight of 4240 and 4226 Dalton, respectively and have identi-
cal residues at 16 positions26. Human PP differs at two to four positions.The amino acid of Human PP
at position 2, 6, 11 and 23 are Proline,Valine,Asparagine and Aspartic acid, respectively27. It appears that
the activity of PP resides in the C-terminal tyrosine amide portion of the peptide because it was
demonstrated that the C-terminal hexapeptide of bovine PP was able to mimic the pharmacologic ac-
tions of the whole molecule while bovine PP deprived of the C-terminal did not28.
11
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Distribution
The pancreas appears to be the major site for production and storage of PP because release of PP
in the blood could not be demonstrated in patients with previous total pancreatectomy29,30. PP pro-
ducing cells occur almost exclusively in the duodenal part of the pancreas. PP is stored in endocrine
F-cells31,32.These PP producing cells can be demonstrated with the light microscope by the use of im-
munocytochemical methods only.With the electron microscope, they are rather small and show round
or slightly ovoid granules of small size and of moderate to high electron density30.The number PP pro-
ducing cells increases with age.A more striking degree of hyperplasia is found in all pathological con-
ditions associated with injury to the pancreatic parenchyma: e.g. mucoviscidosis, pancreatitis, exocrine
and endocrine tumours, hemochromatosis and diabetes33.
Physiological activities
It has been demonstrated that infusion of PP to plasma concentration as observed as after a meal
was able to affect physiological functions28,34. In conscious dogs steady gastric acid secretion induced
by continuous intravenous infusion of 0,5 m g/kg/hr of pentagastrin was significantly inhibited by
bovine PP28.Bovine PP (10 m g/kg/hr) also reduced the water and bicarbonate secretion by about 80%
in dogs with chronic pancreatic fistula28,35. At higher doses, PP has been demonstrated to impair bile
flow into the duodenum by relaxing the gallbladder and by increasing choledochal sphincter tone36,37.
The suppression of pancreatic secretion induced by exogenous or endogenous CCK secretion, the en-
hancement of gastric emptying and intestinal transit and the initial stimulation followed by inhibition
of gut motility are other actions of PP37-39. Administration of PP in dogs decreases intraluminal gall-
bladder pressure with concomitant gallbladder filling following CCK induced gallbladder contrac-
tion40. Furthermore, exogenous PP promotes gallbladder filling in the basal state41.The physiologic im-
portance of these gastrointestinal actions, however, remains to be established.
Radioimmunoassay of PP and metabolism
In the studies performed for this thesis, plasma PP was measured by a sensitive and specific ra-
dioimmunoassay. Radioiodinated PP was prepared by the chloramine-T method as described previ-
ously42.The specific activity of 125I-PP used was about 275 m Ci/ m g. In the radioimmunoassay system,
1 ml of 125I-PP (1800 cpm corresponding to 0.9 fmol of PP), 0.2 ml of anti-PP serum (final dilution
1:900,000), 0.2 ml of standard or sample, and 0.8 ml of veronal buffer, giving a total volume of 2.2 ml,
were incubated for 3 days at 40C.Human PP was used as standard preparation.All dilutions were made
in 0.02 M veronal buffer (pH 8.4) containing 0.02% sodium azide and 0.17% human serum albumin.
Separation of free and antibody-bound PP was carried out using albumin-coated charcoal.The ratio
of bound to free labelled PP was inhibited by 50% at a concentration of 2.8 pM of incubation mix-
ture.The intraassay variation in the steep part of the standard curve was between 4% and 7%, and the
interassay variation was between 6% and 12%.The detection limit of the assay was 0.5 pM of incuba-
tion mixture.
At room temperature, PP is stable for at least 24 hours in whole blood and for 10 days in sterile
plasma. Plasma PP levels remain stable when stored at -20 0C.The plasma PP level is genuine by free-
zing and thawing up to 20 times. Pharmacokinetic data of circulating PP have been determined in
man after infusion of pure 1-36 PP.The disappearance half-life time of PP from the circulation was
calculated to be 6.9 minutes with a clearance rate of 5 ml/kg/min and a distribution volume of 51
ml/kg43. In patients with renal failure, basal PP levels are elevated and the plasma half-life time is pro-
longed demonstrating a significant role of the kidney in the excretion of PP42,44,45.
12
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Regulation of PP secretion
Regulation of pancreatic exocrine secretion is comprised of a complex interplay between hor-
monal and nervous mechanisms25. PP can be released from F-cells in the pancreas by several stimuli.
Infusion of exogenous CCK, leading to plasma CCK concentrations found after a meal, caused sig-
nificant PP release in humans46. Cholinergic pathways, however, play a key role, since subsequent ad-
ministration of atropine abolishes PP release in response to all investigated stimuli47-50.This suggest that
acetylcholine may be the final common pathway by which PP cells are stimulated.
Ingestion of a protein meal is a potent and rapid stimulus for the release of PP.The amount of the
ingested meal corresponds with PP release.A significant increase in plasma PP is seen as early as 3 min-
utes after the beginning of the ingestion. Intravenously administered fat did not result in release of
plasma PP25,51, while ingestion of fat resulted in a three times increase of plasma PP. Ingestion of pro-
tein, however, revealed the most stimulatory effect on PP52,53. Infusion of a mixture of 10 essential
amino acids resulted in a significant but much smaller PP release25.The PP response pattern of carbo-
hydrates is similar, but the PP increment is lower than that to protein or fat. Distension of the stom-
ach, as produced by the ingestion of celery or water results in a modest stimulatory effect on plasma
PP release. Because of the great discrepancy in PP release between ingestion of water/celery and pro-
tein/fat/carbohydrates, it is unlikely that distension of the stomach after ingestion of food is the ma-
jor mechanism for PP release.All these findings and the demonstration that PP is found in the pan-
creas suggests the existence of an entero-PP axis.
Erythromycin
Erythromycin (ERY) was originally isolated from an actinomycete in a soil sample from the Philip-
pines54. It has become established as a safe and useful macrolide antibiotic with a broad spectrum of ac-
tion against many commonly acquired bacterial pathogens55. Since the introduction of ERY into clin-
ical practice, gastrointestinal side effects, commonly nausea and vomiting, cramping upper abdominal
pain, and diarrhoea, have been consistently reported.These side effects may in part be the result of a
change in intestinal flora. However, ample studies demonstrated that ERY exerts powerful stimulato-
ry effects on gastro-duodenal motility56-64. In addition, ERY also stimulates gallbladder emptying and
colonic motility65-70. In vitro, the effects of ERY on isolated smooth muscle strips were not inhibited
by atropine, hexamethonium, naloxone, diphenhydramine, methysergide, procaine, trypsine, in-
domethacin, or sodiumnitroprusside but were blocked by nifedipine, indicating a direct calcium de-
pendent effect of ERY, probably by binding to motilin receptors which are abundantly present in the
gastric antrum49,71. In vivo, however, the effect of ERY on gastrointestinal motility is inhibited by at-
ropine suggesting the importance of cholinergic pathways in this action67,72-74. Jebbink et al, demon-
strated that intravenously administered ERY also stimulated PP secretion67.This effect can be blocked
by atropine indicating that cholinergic pathways play an important role in ERY stimulated PP release
too67.
The role of pancreatic polypeptide in the assessment of vagal
nerve integrity
Basal plasma PP correlates with age. Plasma PP increases about 30 pg/ml per decade75. Basal plas-
ma PP levels may play a role in clinical practice since these levels can be dependent on different dis-
ease states.Abnormally low basal PP values have been reported in patients with obesity76, autonomic
13
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neuropathy77-82, pancreatic insufficiency and pancreatectomy83-85, while high basal PP values have been
demonstrated in patients with duodenal ulcer disease86-89, diabetes mellitus90-94, apudomas95, stressful
events96,97 and sleep deprivation97.
The vagal-cholinergic system plays an important role in the stimulation of PP release, since atro-
pinisation or total vagotomy decreases PP release in response to several stimuli56,57. For this reason, the
secretion of PP is a model of choice for studies of vagal control of endocrine systems at the afferent,
central, and efferent levels of vago-vagal reflexes. In medical practice, stimulation of PP cells is achieved
by central vagal activity induced by sham feeding or acute hypoglycaemia by long vago-vagal or local
gastro-pancreatic or enteropancreatic cholinergic reflexes89,90. Damage of the vagus nerve may result in
a decreased or absent PP response. Sham feeding by the ‘chew and spit’ technique is a rather specific,
but mild stimulation of vagal activity to the gastrointestinal tract resulting in approxiamately 20%
negative results in normal subjects87,98, and ‘Insulin induced hypoglycaemia’ a less specific but a stronger
stimulus.
The PP response during a meal is typically biphasic53.The initial cephalic phase can be eliminated
by vagotomy or atropinisation and can be mimicked by sham-feeding. This phase is followed by a
long-lasting, secondary gastrointestinal phase, which is just blunted by vagotomy53,93. During modified
sham feeding by the ‘chew and spit’ technique there is stimulation of the cephalic phase of the meal
by visual, olphactory, gustatory and masticatory perception.The PP response to modified sham feed-
ing can be further increased by adequate sham feeding, a technique in which patients, equipped with
a rubber tube inserted into the distal part of the oesophagus via a gastrostomy to prevent entrance of
food into the stomach, are allowed to eat and swallow the meal49,87.Distention of the stomach and duo-
denum in itself, e.g. by a water bolus may also stimulate additional PP release by activation of local or
long vago-vagal/gastro-duodeno-pancreatic reflexes99-101. Since the intestinal phase of meal stimulated
PP release is not completely blocked by atropine, it is suggested that activation of peptidergic messen-
gers like CCK or other gut peptides play a role102-105. However, the action of these peptides on PP re-
lease is complex and they all seem to act either through a cholinergic mechanism or against a back-
ground of permissive cholinergic tone106.
PP secretion is not only regulated by food intake but also by blood glucose. Hypoglycaemia sti-
mulates PP release by increasing central vagal activity. Hyperglycaemia inhibits PP release by decreas-
ing central vagal activity.The blood glucose level has no direct effect on the PP cel107. Since vagotomy
leaves the PP cell unresponsive to changes in blood glucose, cholinergic pathways seem to play a key
role92,98,108-110. PP release after insulin induced hypoglycaemia can therefore be used in the assessment of
vagal nerve integrity.
Electrical stimulation of the vagus nerves causes a rapid and considerable release of PP both in pigs
and calves47,111.This response is inhibited by atropine and abolished by hexamethonium, suggesting the
involvement of nicotinic and muscarinic receptors102,103. Electrical stimulation of the vagus nerve is not
used in clinical practice.
Cardiovascular autonomic function tests
The development of simple tests using cardiovascular reflexes has allowed a more precise approach
of autonomic nerve function.These tests reflect both, symptoms112-114 and prognosis104 and it can be as-
sumed that cardiovascular reflex abnormalities indicate diffuse damage throughout the autonomic
nervous system78,115-117.Recently an automated programme has been developed,using a Finapres (FINger
Arterial PRESsure) device and personal computer, to perform a battery of five cardiovascular reflex
tests118.With the use of this programme, cardiovascular autonomic dysfunction can be detected in a sim-
14
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ple and quick way.The tests are based on heart rate and blood pressure variability (both under vagal
control) during forced breathing, standing up, the valsalva manoeuvre and sustained handgrip.
The cardiovascular reflex tests used in this thesis are also performed by this automated method.With a
Finapres device, heart rate (beats/min) and blood pressure (mmHg) are continiously recorded from a
finger.The principle of this instrument is based on servoplethysmomanometry, employing the volume
clamp technique119,120.The digital signal of the Finapres is recorded by a personal computer, by which
means a computer programme could be developed to calculate the test results automatically, immedi-
ately after the tests have been performed.The Finapres cuff (Finapres model 5 TNO Amsterdam) is
wrapped around the middle finger of the non-dominant hand, which is fixed exactly at heart rate
level. Before starting the tests the manoeuvres are trained to perform them correctly, according to the
timeclock of the computer programme. After 5 minutes of supine rest, the subjects perform 6 con-
secutive maximal respirations in 1 minute. Five minutes later the subjects stand up and remain in up-
right position for 2 minutes.After 2 minutes rest in the sitting position the valsalva manoeuvre is per-
formed three times, each after 1 minute rest. Finally the patients are asked to exert 30% of their
previously determined maximum voluntary contraction for 3 minutes on a handgrip dynameter,
2 minutes after the last Valsalva manoeuvre.
During deep breathing at 6 breaths/min, the mean difference between the highest heart rate during
inspiration and the lowest during expiration for six consecutive breathing cycles is calculated118,121.
During the standing up test the programme calculates the difference between the maximum heart rate
after the manoeuvre and the control heart rate before and also the quotient of maximum heart rate and
minimum heart rate after standing up113. Furthermore the difference in averaged diastolic blood pres-
sure between 50 and 80 seconds in the standing position and during the control period is calculated122.
The highest Valsalva ratio of the 3 manoeuvres performed, defined by the maximum heart rate divided
by the lowest heart rate after the manoeuvre, is used to evaluate the heart rate variability during this
test123.During sustained handgrip the highest increase in average diastolic blood pressure over 5 seconds
is considered.The test results are defined as abnormal if the testparameter is below the 5th percentiles of
normal123.Autonomic dysfunction is defined as an abnormal score of 2 or more of the 5 tests118.
Aims and outline of investigations
The purpose of the studies presented in this thesis is to contribute to the knowledge of the physi-
ology and pathophysiology of PP release or gallbladder contraction after stimulation of the vagal-
cholinergic system by several stimuli in healthy subjects and patients with disorders that may involve
the autonomic nerve system.
In chapter 2 and 3 we investigated to what part chemoreceptors are involved in the induction of
vagal activity during MSF.We therefore studied the relevance of the composition of the meal in MSF
induced gallbladder contraction and PP release.
To determine whether long vagal-cholinergic pathways or the gastric antrum are involved in ERY
induced PP release, we studied in chapter 4 the effect of an intravenously administered bolus of ERY
in vagotomized patients with or without antrectomy.
Chapter 5 through 7 deal with ERY or insulin hypoglycaemia stimulated PP release in different pa-
tient groups. In chapter 5 and 6, ERY was administrated in different dosages to determine if ERY
stimulates PP release in a dose dependent way. Insulin hypoglycaemia is the most potent stimulus for
vagal-cholinergic PP secretion.As a test, it can be used to determine vagal nerve integrity. Since this
stimulation test is time-consuming and accompanied by transient side-effects, we studied whether
ERY stimulated PP release could replace the insulin hypoglycaemia test.This is especially important
15
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for patients with diabetes mellitus because it is difficult, time-consuming and hazardous to induce an
acute standardized hypoglycaemia in these patients. Furthermore, we investigated the possible clinical
practical value of the different tests.The results of ERY and insulin hypoglycaemia stimulated PP re-
lease are compared with the cardiovascular reflex test results with respect to gastrointestinal symptoms.
Finally, in chapter 8 the results of the various studies reported in this thesis are discussed and sum-
marized in the light of the questions posed in this chapter.
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Summary
Changes in gallbladder contraction and plasma cholecystokinin release were studied following modi-
fied sham feeding of three different isocaloric meals rich in either fat, protein or carbohydrates in
healthy volunteers, and results were compared with those following real feeding of comparable meals.
In contrast to carbohydrate rich meals (8 – 19 ml*120 min), fat- (-412 – 46 ml*120 min) and pro-
tein rich meals (-352 – 42 ml*120 min) reduced integrated gallbladder volume (p<0.05) in response
to modified sham feeding. Plasma cholecystokinin levels were not significantly influenced by modi-
fied sham feeding of fat, protein or carbohydrates. Real feeding of a carbohydrate rich meal also failed
to significantly reduce gallbladder volume and to stimulate cholecystokinin release (-45 – 40 ml*120
min and 51 – 48 pM*120 min, respectively), while real feeding of both fat- and protein rich meals
distinctly reduced gallbladder volume (-679 – 76 and -564 – 53 ml*120 min, respectively; p<0.05)
and increased cholecystokinin release (651 – 72 and 504 – 44 pM*120 min, respectively; p<0.05).
This study demonstrates that gallbladder contraction during the cephalic phase of meal stimulation is
dependent on the fat-, protein and carbohydrate percentages of a meal, and is activated by different
mechanisms than the intestinal phase of a meal.
Introduction
Sham feeding has been shown to stimulate gastric acid production, gallbladder contraction and
pancreatic exocrine secretion in several species, including man1-6. It is well established, that the re-
sponses to modified and real sham feeding are abolished by atropine and vagotomy5-10.As a result sham
feeding is thought to stimulate vagal cholinergic activity.The mechanisms by which vagal cholinergic
actions are triggered by sham feeding are not completely understood.Although gustatory, olphactory,
acoustic and visual signals are known to be involved in the cephalic phase of meal stimulation3,11, no
data are available on the stimulating effects of the different components of a meal when sham fed.
Thus, this study investigated the contribution of fat, protein and carbohydrates in the stimulation of
vagal cholinergic activity on gallbladder contraction following modified sham feeding in healthy vol-
unteers. In addition plasma CCK levels were measured during modified sham feeding and the results
were compared with those from real feeding of comparable meals in the same subjects.
Methods
Six healthy volunteers (2M, 4F; mean age 58 – 10 years) participated in the study. None was taking
medication or had a history of gastrointestinal disease or surgery.The studies were approved by the
ethical committee.All subjects gave informed consent.Volunteers were studied on three different days
with at least one week in between.After an overnight fast, basal gallbladder volumes were measured
and blood was collected to determine CCK.Meals were subsequently presented to subjects in random
order. Isocaloric (1050 kJ, 250 kcal), isothermic, homogenized meals rich in either fat (walnuts; 66 g
fat, 15 g protein, 7 g carbohydrate per 100 g), protein (codfish; 1 g fat, 23 g protein per 100 g) or car-
bohydrates (bananas; 1 g protein, 22 g carbohydrate per 100 g) were sham fed for thirty minutes by
the ‘chew and spit’ technique12.Gallbladder volumes were determined at fifteen minute intervals twice
before and for two hours after the onset of modified sham feeding. Blood samples to determine CCK
were taken at the same intervals, except for the first 30 minutes following the onset of modified sham
feeding, when blood was drawn at 10-minute intervals.
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Two hours later, comparable meals were ingested and gallbladder volumes and plasma CCK con-
centrations were determined for another 2 h according to the same protocol as the modified sham
feeding period.At each time interval, longitudinal and transverse echograms of the gallbladder were
obtained by real-time ultrasonography as previously described13. Gallbladder volumes were calculated
by computer, based on the sum of cylinders method described by Everson et al.14. Ultrasound shots
were blindly interpreted by two experts who were unbiased to the type of meal or its manner of pre-
sentation. Plasma CCK was measured by a sensitive and specific radioimmunoassay15,16.Antibody T204
binds to all carboxyl-terminal-specific CCK peptides.The antibody shows insignificant (<2%) bind-
ing to sulphated gastrins and does not bind to unsulphated gastrins and structurally unrelated peptides.
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Figure 1a.Gallbladder volume-time curves for the three
different meals during and after modified sham feeding
in six healthy volunteers. Solid dots indicate ‘carbohy-
drate meals’, open dots indicate ‘fat meals’ and open di-
amonds indicate ‘protein meals’. Rectangle, 0-30 min,
indicates the sham-fed meal period. Results are ex-
pressed as mean – SEM.
Figure 1b.Gallbladder volume-time curves for the three
different meals during and after real feeding in six
healthy volunteers. Solid dots indicate ‘carbohydrate
meals’, open dots indicate ‘fat meals’ and open dia-
monds indicate ‘protein meals’. Rectangle, 0-30 min,
indicates the real meal period. Results are expressed as
mean – SEM.
opmaak-witteman  09-11-1998 15:19  Pagina 26
CCK33 coupled to 125I-hydroxy-phenylpropionic acid succinimide ester (Bolton-Hunter reagent) was
used as label. Synthetic CCK33 was used as standard. Separation between free and antibody-bound
hormone was performed by a double-antibody technique.The detection limit of the assay was 0.5
pM.The 50%-inhibition dose was 2.1 pM. CCK was extracted from plasma by ethanol with a recov-
ery of 85 – 2% when 2 - 10 pM of CCK33 was added to hormone-free plasma and 90 – 2% when 2
- 10 pM of CCK8 was added.The intra-assay variation ranged from 4.6 to 11.5% in the working range
of the assay.All samples were measured in the same run.
Results are expressed as mean – standard error of the mean (SEM). Integrated gallbladder- and
CCK-responses were determined by calculating the area under the gallbladder volume-time curve
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Figure 2a. Plasma cholecystokinin concentration-time
curves for the three different meals during and after
modified sham feeding in six healthy volunteers. Solid
dots indicate  ‘carbohydrate meals’, open dots indicate
‘fat meals’ and open diamonds indicate ‘protein meals’.
Rectangle, 0-30 min, indicates the sham-fed meal pe-
riod. Results are expressed as mean – SEM.
Figure 2b. Plasma cholecystokinin concentration-time
curves for the three different meals during and after re-
al feeding in six healthy volunteers. Solid dots indicate
‘carbohydrate meals’, open dots indicate ‘fat meals’ and
open diamonds indicate ‘protein meals’. Rectangle, 0-
30 min, indicates the real meal period. Results are ex-
pressed as mean – SEM.
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and the plasma CCK concentration-time curve, respectively, employing the trapezoidal rule after sub-
traction of basal values17.
Statistical analysis was performed using ANOVA. Differences were considered significant when a
two-tailed p-value was less than 0.05.
Results
Gallbladder volume-time curves for the different meals before and after modified sham feeding or
real feeding are depicted in figure 1a and 1b, respectively. Modified sham feeding of walnuts (fat) and
codfish (protein) markedly reduced gallbladder volume. Integrated gallbladder volume decreased by 
-412 – 46 ml*120 min and -352 – 42 ml*120 min, respectively (p<0.05). However, modified sham
feeding of bananas (carbohydrate) failed to significantly reduce gallbladder volume (8 – 19 ml*120
min). Plasma CCK concentrations were not significantly influenced by modified sham feeding of the
different meals (figure 2a).As in the modified sham feeding experiments, marked gallbladder respons-
es were only observed after real feeding of walnuts (-679 – 76 ml*120 min) and codfish, (-564 – 53
ml*120 min; p<0.01), but not after real feeding of bananas (-45 – 40 ml*120 min).The gallbladder
response to real feeding of walnuts and codfish was more pronounced than to modified sham feeding
(p<0.05). In contrast to modified sham feeding, real feeding of both walnuts and codfish, induced sig-
nificant increases (P<0.05) in plasma concentrations of CCK of 651 – 72 pM*120 min, and 504 – 44
pM*120 min, respectively (figure 2b). Real feeding of bananas only induced a slight increase in plas-
ma CCK concentrations (51 – 48 pM*120min).
Discussion
The present study shows that gallbladder contraction in response to modified sham feeding is de-
pendent on the composition of the meal. Fat and protein, but not carbohydrates are potent stimuli for
gallbladder contraction in response to modified sham feeding.The gallbladder response to modified
sham feeding shows striking qualitative similarities to the gallbladder response to real feeding of fat,
protein or carbohydrate enriched meals18, suggesting activation of a comparable perceptive mechanism
during cephalic and intestinal stimulation. However, the subsequent events that are responsible for the
reduction in gallbladder volume after perception of the stimulus of modified sham feeding and real
feeding are different. In contrast to modified sham feeding, real feeding of fat or protein significantly
stimulates plasma CCK concentrations. CCK has been shown to be an important stimulus for gall-
bladder contraction under physiological conditions19-23. Infusion of CCK to values comparable to
those obtained after ingestion of walnuts and codfish has been shown to induce similar gallbladder re-
sponses23.The reduction in gallbladder volume in response to real feeding of walnuts and codfish can
therefore largely be explained by the release of CCK.
The absence of CCK responses to modified sham feeding also indicated that the volunteers were
adequately sham fed and that meals were not swallowed during the modified sham feeding tests.
While the gallbladder response to modified sham feeding can be abolished by atropine and truncal
vagotomy1-10, this substance and process do not fully suppress gallbladder responses or CCK release to
real feeding24-26. Furthermore, a complete suppression of gallbladder contraction in response to real
feeding, but not to modified sham feeding, has been observed after administration of specific CCK re-
ceptor antagonists19,27.
All these data indicate that gallbladder contraction in response to modified sham feeding is under
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vagal cholinergic control, while gallbladder contraction during real feeding is largely mediated by
CCK release.
How modified sham feeding of fat or protein stimulates efferent routes to the brainstem, remains
to be elucidated. Mechanical, gustatory, visual, acoustic and olphactory factors may all be involved.
Conditioned acoustic and visual signals were probably not involved in gallbladder emptying after sham
feeding of protein or fat in the present study, since no gallbladder contraction was observed before the
homogenized meals were tasted, since acoustic stimuli were comparable due to randomization and
since the three meals were hardly distinguishable visually.A delay in gallbladder emptying in response
to acoustic and visual stimuli overlapping the response tasting meals is also unlikely, since no gallblad-
der emptying was observed after sham-feeding of carbohydrates, while acoustic and visual stimuli that
preceeded meal tasting were comparable.Activation of mechanoreceptors by mastication11,28 probably
cannot explain the difference in gallbladder response between fat and protein meals on one hand and
the carbohydrate meal on the other either, since all meals were homogenized.Activation of osmore-
cepters or thermoreceptors is also unlikely, since all homogenized meals were isocaloric and served at
room temperature. However, activation of olphactoric factors by the different meals could not be ex-
cluded, since the odor of the meals could not be neutralized.
Since gallbladder responses to modified sham feeding and real feeding show similarities depending
on the chemical composition of a meal, it would seem that although chemoreceptors sensitive to pro-
tein and fat but not to carbohydrates, are the major perceptive receptors in digestive tract mucosa,
these receptors subsequently activate other mechanisms to obtain gallbladder responses, depending on
where the stimulus is recieved. In the present study, olphactoric and gustatoric chemoreceptors acti-
vated by protein and fat but not by carbohydrates stimulated CCK-independent vagal cholinergic
mechanisms via the brain stem during sham-feeding, while intestinal chemoreceptors activated by
protein and fat, but not by carbohydrates stimulated the release of CCK and induced gallbladder emp-
tying during real feeding.
In conclusion, gallbladder contraction in response to modified sham feeding appears to be depen-
dent on the composition of the meal.The same nutrients that stimulate gallbladder contraction dur-
ing the intestinal phase also stimulate gallbladder contraction during the cephalic phase of a meal, al-
though via different mechanisms, since real feeding but not modified sham feeding stimulates the
release of CCK.
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Abstract
Objective:To study the effect of meal composition on pancreatic polypeptide release during modified
sham feeding.
Design: In random order and on separate occasions, iso-caloric, iso-thermic, iso-osmotic, homoge-
nized meals (250 kcal) either rich in fat (walnuts; 66 g fat, 7 g carbohydrate, 15 g protein per 100 g),
protein (codfish; 1 g fat, 23 g protein per 100 g) or carbohydrate (bananas; 22 g carbohydrate, 1 g pro-
tein per 100 g) were sham fed for 30 minutes by tasting and spitting out the meal.The plasma pan-
creatic polypeptide response was monitored by radioimmunoassay at 10 minute intervals from 20
minutes before to 120 minutes after modified sham feeding.
Setting: Department of Gastroenterology and Hepatology of a University Hospital.
Subjects: Seven healthy volunteers: 3 male, 4 female; age 45 (range 30-77 yrs) were studied.
Results: Integrated plasma pancreatic polypeptide responses to modified sham feeding of codfish
(1088– 395 pM*120min; p<0.05) and walnuts (1200 – 542 pM*120min) were distinctly higher
(p<0.05) than to modified sham feeding of bananas (-390 – 291 pM*120min).
Conclusions: These results demonstrate that the pancreatic polypeptide response to modified sham
feeding is dependent on the composition of the meal.
Introduction
Sham feeding of a meal has been shown to stimulate gastric acid production, gallbladder contrac-
tion and pancreatic exocrine secretion in different species including man1-6. Several studies have
demonstrated that these responses to sham feeding are under vagal cholinergic control5-11. Although
the mechanism by which sham feeding triggers vagal cholinergic activity is not completely under-
stood, it is believed that gustatory, olfactory, acoustic, mechanic and visual signals are involved3,12-14.To
what part the composition of a meal is of importance is presently not known.We therefore have stud-
ied the effect of bananas (carbohydrate), codfish (protein) and walnuts (fat) on the pancreatic polypep-
tide (PP) response to modified sham feeding (MSF) in healthy volunteers.
Methods
Ten healthy volunteers (4M, 6F) with a median age of 48 years (33 to 77 years), participated. None
of the volunteers used any medication, had a history of pancreatic disease or had undergone ab-
dominal surgery that could possibly interfere with the PP response to MSF.The subjects were studied
on three different days separated by at least one week. In random order, after an overnight fast iso-
caloric (1050 kJ; 250 kcal), iso-thermic, iso-osmotic, homogenized meals either rich in fat (walnuts; 66
g fat, 15 g protein, 7 g carbohydrate per 100 g), protein (codfish; 1 g fat, 23 g protein, 0 g carbohydrate
per 100 g) or carbohydrate (bananas; 0 g fat, 1 g protein, 22 g carbohydrate per 100 g) were sham-fed
for 30 minutes by tasting and spitting out the whole meal7.The subjects were strongly encouraged not
to swallow any food.At the end of each study they were asked to score appetizing and savory aspects
of the different meals on a visual analogue scale (0-10; 5 being neutral). Blood samples for PP and
cholecystokinin (CCK) were taken at 10 minute intervals, two times before and for two hours after
the start of MSF of the different meals. In order to demonstrate that the subjects who participated in
this study were able to release PP, 30 g of fat was consumed several weeks before the MSF tests, and
PP responses were determined at 15 min intervals for 120 minutes. Only those subjects who showed
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an increase in plasma PP levels of at least 50 pM in response to this fat meal were selected for the MSF
tests.
The basal PP level was taken as the mean of two unstimulated samples. Plasma PP and CCK were
measured by a sensitive and specific radioimmunoassay. Radioiodinated PP was prepared by the chlo-
ramine-T method14,15. The specific activity of 125I-PP  used in this study was approximately 275
m Ci/m g. In the radioimmunoassay system, 1 ml of 125I-PP  (corresponding to 0.9 fmol of PP), 0.2 ml
of anti-PP serum (final dilution 1:2000,000), 0.2 ml of standard or sample, and 0.8 ml of assay buffer,
giving a total volume of 2.2 ml, were incubated for 4 days at 4°C. Human PP was used as standard
preparation.All dilutions were made in 0.02 M sodium barbital buffer pH 8.4, containing 0.02% sodi-
um azide and 0.17% human serum albumin. Separation of free and antibody-bound PP was carried
out using albumin-coated charcoal.The ratio of bound to free labelled PP was inhibited by 50% at a
concentration of 4.5 pM of incubation mixture.The intra-assay variation in the steep part of the stan-
dard curve ranged between 4% and 7%, while the inter-assay variation ranged between 6% and 12%.
The detection limit of the assay was 0.5 pM of incubation mixture.All samples were measured in du-
plicate in the same run.
Integrated PP responses were determined by calculating the area under the plasma PP concentra-
tion-time curve by the trapezoidal rule after subtraction of basal values. Results are expressed as mean
– standard error of the mean (SEM). Differences were tested for statistical significance by the analysis
of variance (ANOVA) and subsequently by the
least significant difference method (LSD)16. Dif-
ferences were considered significant when the
probability value was equal or lower than 0.05.
The study protocol was approved by the local
ethical committee and all subjects gave their in-
formed consent.
Results
Two female volunteers (both age 48) were ex-
cluded from the study because their increase in
PP-release after ingestion of a 30 g fat meal nev-
er exceeded 50 pM, suggesting that PP-cells
might not be intact in these subjects. After each
MSF the subjects were asked if they accidently
had swallowed a part of the meal. One female
volunteer (age 67) was excluded from the study
because she accidently had ingested parts of the
carbohydrate and protein rich meals during sham
feeding.The possibility of meal ingestion was fur-
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Figure 1: Delta PP response-time curves for walnut,
codfish and banana meals after modified sham feeding
in seven healthy volunteers. closed dots indicate ‘banana
meal’, open dots indicate ‘walnut meal’ and open dia-
monds indicate ‘codfish meal’. Results are expressed as
mean – SEM.
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ther eliminated in the MSF experiments by failure to demonstrate any CCK release (data not shown).
Plasma PP concentration-time curves for each of the different meals in response to MSF in the re-
maining 7 healthy subjects are depicted in figure 1. Unstimulated plasma PP-levels at -10 and at 0 min
were 45– 12 pM and 44 – 13 pM for bananas, 37 – 12 pM and 33 – 9 pM for codfish and 29 – 5 pM and
33– 9 pM for walnuts, respectively (not significant). Integrated PP-responses markedly increased after
MSF of codfish (protein) and walnuts (fat) to 1080 – 395 pM*120min (p<0.05) and 1200 – 542
pM*120min (p=0.05) respectively, while MSF of bananas (carbohydrates) failed to significantly in-
crease integrated plasma PP values (-390 – 291 pM*120min).The PP responses to codfish and walnuts
were significantly (p<0.05) higher than the PP responses to bananas. Most subjects enjoyed the pre-
sentation and sight of the meals. Scores were identical for the different meals (all > 7). One subject
found MSF of bananas offensive, and 2 other subjects disliked walnuts (scores < 5).The PP responses
in these series, however, were not different from the results obtained from the other volunteers.
Discussion
The present study demonstrates that the PP response to MSF is dependent on the composition of
the meal. In contrast to bananas; codfish and walnuts proved to be potent stimuli for the release of PP
by MSF. Numerous studies have demonstrated that during and after consumption of a meal, PP is re-
leased in a biphasic manner: the initial phase of PP release is predominantly under cholinergic control,
whereas the secondary prolonged PP response is the result of a synergistic action of hormonal stimu-
lation and vagal activity. Of the hormones, cholecystokinin (CCK) is a major regulator of PP re-
lease1,2,17-22. Previously, we have demonstrated that consumption of fat and protein, but not carbohy-
drates, potently stimulates CCK release23,24.Therefore, it is likely that fat and protein activate the release
of peptidergic messengers like CCK, that in turn mediate release of PP during the intestinal phase of
a meal. However, CCK is not responsible for the effects of fat, protein or carbohydrates during the
cephalic phase of a meal, since CCK is not released during this phase24,25.The absence of CCK release
in the present study also demonstrates that meals were not swallowed accidentally, since 2 grams of
consumed fat already stimulate the release of CCK26. Furthermore, CCK has been demonstrated to be
entirely responsible for the release of PP during the intestinal phase of a meal27, while during the gas-
tric phase of a meal PP is only released by gastric distention to an extent that normally cannot be
achieved by ingestion of a small part of the sham fed meals11.Therefore, PP release in our experiments
can only be explained by cephalic stimulation in response to sham feeding.
How MSF of protein and fat stimulates central vagal mechanisms and vagal efferent routes to the
PP-cell, is presently not known. It is believed that activation of mechano-receptors by distention may
play an important role in the stimulation of PP release.This is illustrated by MSF of water which does
not release PP, while real sham feeding (MSF and swallowing while the meal is diverted from the oe-
sophagus before it reaches the stomach) of a meal results in a more intense release of PP7,28. Since all
meals were homogenized and different responses were obtained from carbohydrates and fat or protein,
activation of mechano-receptors by mastication does not explain the differences in PP response to the
different meals in the present study.Activation of osmo-receptors or thermo-receptors is also unlike-
ly, since all meals were iso-osmotic and served at room temperature. Due to randomization of the dif-
ferent experiments, activation by conditioned acoustic signals that could result in anticipated PP re-
lease could not be an important factor.The visual aspects of the different meals also played a minor
role because all subjects enjoyed the appetizing appearance of each of the meals equally.These results
correspond with those of Feldman and Richardson3 who demonstrated that the sight of a meal was of
minor importance in cephalic stimulation of gastric acid secretion.Therefore, activation of gustatory
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and olfactory mechanisms are the only remaining factors that play an important role in PP release dur-
ing the cephalic phase of these meals.Aside from a difference in smell and taste of the meals, that may
after all largely be determined by the kind of protein, fat or carbohydrates in the meals, our data sug-
gest that PP-release is mainly the result of the amount of protein or fat in the meals.The fact is that a
similar pattern of PP release is seen in response to the intestinal phase of protein, fat or carbohydrate
meals29, which suggests that the amounts of fat, protein and carbohydrates in a meal play a more im-
portant role than its smell or taste.We therefore suggest that the same type of (chemo)receptors are
triggered by nutrients throughout the intestine, but that these (chemo)receptors subsequently activate
endocrine, paracrine or neurocrine mechanisms depending on their location in the intestinal tract.
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Abstract
To determine whether long vagal cholinergic pathways are involved in erythromycin induced pan-
creatic polypeptide release, erythromycin was administered as an intravenous bolus injection to 9
healthy volunteers (group A) and to 13 patients (group B) with impaired vagal function as a result of
truncal vagotomy or accidental vagotomy after anti-reflux surgery. In 7 of these patients (group B1) an
antrectomy was also performed, while in the other 6 patients (group B2) the antrum was not removed.
Pancreatic polypeptide was measured by radioimmunoassay at 5 minute intervals twice before and at
2, 5, 10, 15, 30, 45 and 60 minutes after a 3.5 mg/kg injection of erythromycin.On another day, a stan-
dard meal was administered and plasma pancreatic polypeptide was measured at 10 minute intervals
for 1 h. Erythromycin injection resulted in a lower integrated pancreatic polypeptide response in the
patients of group B1 (247 – 89 pM*15min; p=0.005) and group B2 (497 – 111 pM*15min; p=0.05)
when compared to the healthy subjects of group A (1136 – 227 pM*15min).The pancreatic polypep-
tide response to erythromycin in group B1 was reduced when compared to group B2 but the differ-
ence just failed to reach statistical significance (0.05 < p < 0.1). In the first 30 minutes after ingestion
of a meal (cephalic phase) pancreatic polypeptide release was also markedly lower in group B1
(1461– 304 pM*30min;p<0.005) and group B2 (1452 – 215 pM*30min; p<0.005) when compared to
group A (3541– 452 pM*30min). However, in the second 30 minutes after ingestion of a meal (in-
testinal phase), no significant difference in pancreatic polypeptide response was observed between
group A, B1 and group B2 (3689 – 690 pM*30min, 3319 – 938 pM*30min and 3119– 761 pM*30min,
respectively).These last results demonstrate that pancreatic polypeptide cells were in fact functional in
all patients and controls.We conclude that the effect of erythromycin on pancreatic polypeptide re-
lease is is at least in part dependent on intact long vagal cholinergic pathways. Furthermore, preserva-
tion of the antrum seems to be of importance for erythromycin induced pancreatic polypeptide re-
lease.
Introduction
Erythromycin (ERY) has been demonstrated to exert stimulatory effects on gastroduodenal,
colonic and gallbladder motility1-10. In vitro, the effects of ERY on isolated smooth muscle strips were
not inhibited by atropine, hexamethonium, naloxone, diphenhydramine, methysergide, procaine,
trypsin, indomethacin or sodium nitroprusside but were blocked by nefidipine, indicating a direct cal-
cium-dependent effect of ERY.This is probably the result of binding of ERY to motilin receptors,
which are abundantly present in the gastric antrum2,11. In vivo, however, the effect of ERY on gas-
trointestinal motility is blocked by atropine suggesting that cholinergic pathways play an important
role in this action12-14.The release of pancreatic polypeptide (PP) is largely controlled by the choliner-
gic system and cholecystokinin (CCK)15. Recently, it has been shown that intravenously administered
ERY also stimulates the secretion of PP6.The effects of ERY on PP-release can be blocked by atropine
but not by the specific CCK receptor antagonist loxiglumide indicating that cholinergic pathways
play a mayor role6. It is not known whether the stimulation of PP-cells by ERY is mediated either cen-
trally via the vagal nerve or locally by gastro/entero-pancreatic cholinergic reflexes.The present study
was performed to determine the role of long vagal and local gastropancreatic reflexes in ERY induced
PP-release.
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Subjects and methods
Nine healthy subjects (group A; 3 F, 6 M; age 49– 12 years) and 13 patients (group B; 1F, 12 M; age
53– 8 years) with impaired vagal nerve function as a result of intentional (n=6) or accidental vagoto-
my after anti-reflux surgery as demonstrated by a very low PP release (PP peak increment < 50 pM)
in response to insulin hypoglycaemia15 participated in the study.The patients and healthy subjects were
without any medication for 7 days prior to the tests. No pancreatic disease, renal failure, diabetes
mellitus or liver dysfunction was demonstrable in the patients. In 7 patients the antrum had also been
removed (group B1; 1 F, 6 M; 55 – 8 years). In two of these patients a Billroth I anastomosis was
constructed while in the remaining 5 a Billroth II reconstruction was performed.All patients of group
B2 (6 M, 51 – 7 years) had an intact antrum. In 2 patients of group B2 a highly selective vagotomy 
was performed, and in 2 other patients a pyloroplasty. Patients were studied at least 6 months after
surgery.
After an overnight fast, blood samples for PP were taken at 5 minute intervals twice before and at
2, 5, 10, 15, 30, 45 and 60 minutes after an intravenous bolus injection of 3.5 mg/kg ERY (ery-
throcineR I.V.,Abbott). On another day a standard meal consisting of 2 slices of buttered bread with
50 g of cheese, a boiled egg and 200 cc of tea with 10 g of sugar, was consumed over a 20 minute pe-
riod and plasma PP values were monitored for one hour at 10 minute intervals. Plasma PP was mea-
sured by a sensitive and specific radioimmunoassay16.The specific activity of 125I-PP used in the assay
was 275 m Ci/m g. In the radioimmunoassay system, 1 ml of 125I-PP (1800 cpm corresponding to 0.9
fmol of PP), 0.2 ml of anti-PP serum (final dilution 1:2000,000), 0.2 ml of standard or sample, and 0.8
ml of barbital (veronalR) buffer containing 0.02% sodium azide and 0.17% human serum albumin, pH
8.4,were incubated for 4 days at 4oC.Human pancreatic polypeptide was used as standard preparation.
Separation of free and antibody-bound PP was carried out using albumin-coated charcoal.The ratio
of bound to free labelled PP was inhibited by 50% at a concentration of 4.5 pM of incubation mix-
ture.The intraassay variation in the steep part of the standard curve ranged between 4% and 7%, and
the interassay variation ranged between 6% and 12%.The detection limit of the assay was 0.5 pM of
incubation mixture.
The mean of 2 unstimulated samples was taken as the basal PP level.The integrated incremental PP
values were determined by calculating the area under the individual plasma concentration-time curves
after subtraction of the mean basal value. Statistical analysis was performed a two sample t-test.Values
are expressed as mean – SEM.The study protocol was approved by the local ethical committee and all
subjects gave their informed consent.
Results
PP-release in response to insulin hypoglycaemia in healthy subjects (group A) and in patients with
truncal or accidental vagotomy is shown in figure 1. Delta PP-concentration-time curves for groups
A, B1 and B2 after stimulation with ERY are depicted in figure 2, while figure 3 illustrates the results
after a meal. Stimulation with ERY resulted in a distinctly lower (p<0.001) integrated PP response in
the patients of group B (362 – 76 pM*15min) when compared to the healthy subjects of group A
(1136– 227 pM*15min). Integrated PP values after injection of ERY just failed to reach a statistically
significant difference between vagotomized patients with (group B1: 247– 89 pM*15min) or without
(group B2: 497– 111 pM*15min) antrectomy (0.05 < p < 0.1). Integrated PP-values in group B1 and
group B2 were significantly lower than those in group A (p=0.005 and p=0.05, respectively). During
the cephalic phase of the standard meal (0-30 min), integrated PP release was also markedly lower
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Figure 1: PP responses to insulin (0.1 E/kg of Ac-
trapid) induced hypoglycaemia in the 7 patients with
accidental vagotomy due to antireflux surgery (open cir-
cles; 16 – 8 pM), in 6 patients with truncal vagotomy
(open squares; 13 – 16 pM) and in 9 healthy subjects
(closed dots; 278 – 171 pM). Results are expressed as
mean – SD.
Figure 2: Delta PP-time curves after stimulation with
an intravenously administered bolus injection of ERY
(3.5mg/kg) in 9 healthy volunteers (group A; closed
dots), 7 vagotomized patients with (group B1; open
dots) and 6 vagotomized patients without (group B2;
crosses) antrectomy. Results are expressed as mean –
SEM.
Figure 3: Delta PP-time curves after ingestion of a
meal in 9 healthy volunteers (group A; closed dots), 7
vagotomized patients with (group B1; open dots) and 6
vagotomized patients without (group B2; crosses)
antrectomy. Results are expressed as mean – SEM
1 2
3
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(p<0.001) in group B (1457 – 184 pM*30min) when compared to group A (3541 – 452 pM*30min).
During the intestinal phase of the meal (30-60 min) no statistically significant differences in integrat-
ed PP responses were observed between groups A and B (3689 – 690 pM*30min and 3227– 591
pM*30min, respectively). Integrated meal-stimulated PP responses in groups B1 and B2 did not signif-
icantly differ from each other in the cephalic phase (1461 – 304 pM*30min vs 1452 – 215 pM*30min),
and in the intestinal phase (3319 – 938 pM*30min vs 3119 – 761 pM*30min).
Discussion
The present study demonstrates that ERY stimulates the release of PP into the systemic circulation,
and that this release is strongly dependent on long vagal nerves innervating an intact antrum. In addi-
tion the present study confirms that PP-release during the cephalic phase of a meal is impaired in pa-
tients with vagal nerve damage15.The finding that PP release during the intestinal phase of a meal did
not significantly differ between patients and healthy subjects indicates that the decreased PP response
to the cephalic phase of a meal and to ERY administration in patients with truncal or accidental vago-
tomy was not the result of incapability of PP-cells to produce PP.
The mechanism by which ERY stimulates PP-release remains speculative.Theoretically ERY may
stimulate PP-release by direct effects on PP-producing cells in the pancreas or by indirect effects me-
diated by endocrine, paracrine or neurocrine mechanisms. A cholinergic dependent neural mecha-
nism seems quite probable, since PP release in response to ERY can be blocked by atropine6.Thus, ac-
tivation of local gastroduodenopancreatic cholinergic mechanisms, periferal activation of long
vago-vagal mechanisms, or direct stimulation of vagal cholinergic mechanisms in the central nervous
system may be responsible for PP release after injection of ERY.
It has previously been demonstrated that ERY binds to motilin receptors, which are abundantly
present in the gastric antrum2,11,21. Binding of Leu13-motilin to motilin receptors on smooth muscle
cells has also been demonstrated to stimulate the release of acetylcholine from enteric nerves17.There-
fore, binding of ERY to motilin receptors in the antrum and subsequent activation of local gas-
tropancreatic cholinergic pathways may at least in part account for the small amounts of PP released
by ERY injection in patients with intentional or accidental vagotomy and an intact stomach. In
antrectomized patients, the number of motilin receptors is consequently diminished, resulting in a fur-
ther reduction of PP release to ERY injection, as shown in the present study.Activation of long vagal
pathways, however, remains the most important mechanism to explain PP release by ERY infusion,
since in comparison with control subjects, the majoity of PP release in response to ERY is suppressed
in vagotomized patients. However, it is not clear whether ERY activates central or peripheral mecha-
nisms that are dependent on intact long vagal pathways. By stimulating peripherally located vagal sen-
sory endings or motilin receptors in the upper gastrointestinal tract, ERY may induce PP release
through vago-vagal nerves switching in the brain stem.This is supported by recent findings in rats and
ferrets, where it has been demonstrated that such digestive vagal sensory endings exhibit chemosensi-
tivity18-20.
Motilin receptors are not only present peripherally in the stomach, but also in the central nervous
system, where motilin immunoreactivity has also been demonstrated22.Therefore, ERY may bind to
motilin receptors in the central nervous system to stimulate PP release through efferent vagal cholin-
ergic pathways. However, ERY does not pass readily into the spinal fluid. Even at high serum levels
(40 ug/ml) after intravenously administration of comparable doses of ERY (300 mg) as used in the
present study, spinal fluid levels remained low (0.04 ug/ml)23. Since we have not measured serum or
liquor concentrations of ERY and since we do not know the threshold concentration of ERY that ac-
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tivates PP-release, we are not able to answer the question whether ERY activates PP-release either by
central or peripheral mediated vagal cholinergic mechanisms.
Because differences in the PP response to 3.5 mg/kg of ERY were highly significant between
vagotomized patients and controls, we have not tested lower doses of ERY to investigate whether the
small release of PP in vagotomized patients disappears by administration of lower doses of ERY. In ad-
dition, we cannot exclude with certainty that the small amounts of PP released by ERY, or during the
cephalic phase of the meal, in vagotomised patients are explained by other mechanisms, for instance,
by enhancement of gastric emptying, which is delayed after vagotomy. By accelerating gastric empty-
ing in vagotomized patients, ERY infusion or cephalic stimulation may result in delivery of gastric
juice or meal residues to the duodenum and subsequently in the release of PP by intestinal distention
by the juice or by the intestinal phase of a meal15, despite the fact that patients restrained from eating
for 15 h prior to the study.
Whatever the mechanism of ERY induced PP release may be, long vagal cholinergic pathways
seem to be involved.ERY-induced PP release may therefore be helpful in detecting long vagal cholin-
ergic damage, for instance, after anti-reflux surgery or in diabetics with autonomic neuropathy. Since
the insulin hypoglycaemia test and the sham-feeding test that are currently used to demonstrate vagal
nerve damage15, are not without risks and often difficult to achieve especially in diabetics, ERY infu-
sion may replace these tests to demonstrate long vagal nerve damage as a consequence of autonomic
neuropathy.
In conclusion, the present study demonstrates that PP release in response to intravenous adminis-
tration of ERY is to a large extent dependent on intact long vagal pathways.The diminished PP res-
ponse to ERY in vagotomized patients is further reduced by antrectomy, suggesting that ERY activates
long vago-vagal and to a lesser extent local gastropancreatic cholinergic reflexes. We speculate that
ERY stimulates vagal sensory endings in the antrum by bindin to motilin receptors.
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Abstract
Autonomic neuropathy of the gastrointestinal tract may alter vagal nerve integrity and frequently
complicates the course of chronic liver disease.Because impaired PP secretion may reflect dysfunction of
the autonomic nerve system of the gastrointestinal tract, the aim of this study was to compare plasma PP
responses to intravenous injection of erythromycin and to modified sham feeding in 11 patients with cir-
rhosis of the liver (Group A) classified as Child A (n=8) or Child B (n=3) and 20 controls (Group B). In
addition cardiovascular reflex tests (finapres) were performed in all patients with chronic liver disease.
Integrated plasma pancreatic polypeptide levels after stimulation with 0.4 and 1.2 mg/kg.15min of
erythromycin were decreased in group A compared to group B (509 [121-2290] vs 1021 [326-2964]
pM*20min (p<0.1), and 776 [29-2670] vs 1228 [514-7608] pM*20min (p<0.05), respectively).After
modified sham feeding, integrated pancreatic polypeptide responses in group A (923 [65-4505]
pM*60min) tended to be lower than those in group B (1580 [473-5115] pM*60min; n=8) but the
results did not reach statistical significance.
It is concluded that the pancreatic polypeptide response to erythromycin but not to modified sham
feeding is significantly decreased in patients with chronic liver disease classified as Child A or B.
Introduction
Autonomic neuropathy (AN) frequently complicates the course of the disease in patients with dia-
betes mellitus, cerebrovascular diseases, spinal cord lesions, Parkinson’s disease and Shy Drager syn-
drome.AN has also been described in chronic liver disease,where its presence may identify a subgroup
of patients with a substantial dismal outlook1,2. Cardiovascular reflex tests, based on heart rate and
blood pressure variability induced by forced breathing, standing up, the Valsalva manoeuvre and sus-
tained handgrip are most commonly used to detect AN3. It is generally accepted that adequate assess-
ment of autonomic nerve function should be based on a series of distinct tests rather than on a single
investigation concerning one reflex system.The automated computerized method using “Finapres”
for measuring cardiovascular reflexes has proven to be very useful for the detection of cardiovascular
AN4.Whether the results obtained with this method may also predict AN of the gastrointestinal tract,
remains to be established.
At the moment, several tests have been described to evaluate vagal nerve integrity of the gastroin-
testinal tract.The release of pancreatic polypeptide (PP) plays a central role in most of these tests be-
cause the secretion of PP is unique in the way that cholinergic, vagal stimulation is not only the most
powerful stimulus, but also the key through which other mechanisms act5. Impaired PP secretion may
therefore be used, as a sensitive indicator of AN of the gastrointestinal system. PP release by stimula-
tion of cholinergic pathways can be achieved e.g. by insulin induced hypoglycaemia, modified sham
feeding (MSF) or electrical stimulation of the vagal nerve5. It has been shown that intravenous injec-
tion of erythromycin (ERY), also stimulates the secretion of PP6,7.The effects of ERY on PP release
can be blocked by atropine, but not by the specific cholecystokinin receptor antagonist loxiglumide,
indicating the involvement of cholinergic pathways6. In a previous study we have demonstrated that
ERY stimulated PP release is dependent on intact vagal-cholinergic pathways7.
Because impaired PP secretion may reflect dysfunction of the autonomic nerve system of the gas-
trointestinal tract, the aim of this study was to compare plasma PP responses to intravenous injection
of erythromycin and to modified sham feeding between patients with cirrhosis of the liver and con-
trol subjects. In addition cardiovascular reflex tests (finapres) were performed in patients with chronic
liver disease.
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Subjects and methods
The PP-response to stimulation with ERY was determined in 11 patients with cirrhosis of the liv-
er (group A; 4F, 7M; median age 46 [26-65] years) and in 20 controls with abdominal complaints
(group B; 9F, 11M; median age 45 [21-71] years). Median Quetelet-indexes of groups A and B were
24.6 [16.5-32.9] and 24.3 [16.9-42.8], respectively. Only patients with histologically proven cirrhosis
of the liver or patients with biochemical and clinical evidence of chronic liver disease with oes-
ophageal varices and/or splenomegaly, participated in the study. One patient had primary biliary cir-
rhosis, 1 had cirrhosis as a result of primary sclerosing cholangitis, 3 had alcoholic liver cirrhosis, 2 had
autoimmune hepatitis with portal hypertension and 4 patients had cryptogenic cirrhosis of the liver.
Three of the patients were classified as Child B (1F, 2M; age 66, 58, 26 year, respectively),while all oth-
er patients were classified as Child A. Six patients had been treated with sclerotherapy for variceal
bleeding. The period between the last sclerotherapy treatment and the present study was at least 3
months.These patients were also included since it has been demonstrated that sclerotherapy does not
affect vagal nerve integrity on the long term8.The control subjects were all on treatment in the out-
patient clinic for mild abdominal complaints. Eight of these controls met the criteria of irritable bo-
wel syndrome, 4 had proctitis and 3 had Crohn’s disease (all in remission), 4 had non ulcer dyspepsia
and one had colonic polyps. Patients with diabetes mellitus, recent alcohol abuse (3 months), previous
upper abdominal surgery, neurological disease, pancreatic insufficiency, cardiovascular disease or sub-
jects on medication that could possibly influence test results and that could not be stopped at least 3
days before the tests,were excluded from the study.All patients of group A but only 9 patients of group
B gave informed consent to the MSF study.
After an overnight fast, blood samples for PP were taken at -5 min, immediately before and at 5,
10, 15, 20, 30, and 60 min after intravenous injection of 0.4 mg/kg.15min and 1.2 mg/kg.15min of
ERY (ErythrocinR,Abbott Laboratories, Berks, England). ERY was injected over a 15 minute period.
The interval between the ERY tests was at least 1 hour. One hour after the last ERY test, a standard
meal consisting of 2 slices of buttered bread with 50 g of cheese, a boiled egg and 200 ml of tea with
10 g of sugar, was sham fed over a 20 min period by the chew and spit technique. During the MSF
study subjects were encouraged not to swallow any of food. For further surveillance CCK was mea-
sured at regular intervals to monitor inadvertent swallowing of food.Two times before, during and af-
ter MSF, plasma PP and plasma CCK values were monitored for 1 hour at 10 min intervals. One hour
after MSF, a meal was ingested over 20 minutes to investigate if PP cells were capable to produce and
release PP. PP responses were determined subsequently at 10 min intervals for 40 minutes. Plasma PP
and CCK were measured by sensitive and specific radioimmunoassays as previously described9,10.
Cardiovascular reflex tests were monitored by an automated computerized method using a Finapres
device (FINger Arterial PRESsure; Finapres model 5;TNO,Amsterdam,The Netherlands)4.With this
device, heart rate (beats/min) and blood pressure (mmHg) were continuously recorded.The principle
of this instrument is based on servo-plethysmo-manometry, employing the volume clamp tech-
nique11,12.The digital signal of the Finapres was recorded using a personal computer. Subsequently, the
test results were calculated automatically by a computer program, immediately after performing the
manoeuvres4. The reproducibility of this program is slightly better than that of the conventional
method, using a sphygmomanometer and electrocardiogram4. Normal values, corrected for age and
sex, were obtained in 124 healthy volunteers.The Finapres cuff was wrapped around the middle fin-
ger of the non-dominant arm, which was fixed at heart level. Each subject was tested at the same time
of the day. Before starting the tests, the manoeuvres were trained to perform them correctly, accord-
ing to the time-clock of the computer program.All subjects refrained from smoking and caffeine- or
alcohol-containing beverages for at least 12 hours. After 5 min supine rest, six consecutive forced
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breathings were performed in one minute.The subjects stood up 5 minutes later in 2-3 seconds and
remained in the upright position for 2 minutes.After 2 minutes rest in the sitting position, the Valsal-
va manoeuvre (expiratory pressure of 40 mmHg for 15 seconds) was performed three times, each af-
ter 1 minute rest. Finally, the subjects were asked to exert 30% of their previously determined maxi-
mum voluntary contraction for 3 minutes on a handgrip dynameter, 2 minutes after the last Valsalva
manoeuvre. During forced breathing, the mean difference between the highest heart rate in inspira-
tion and the lowest in expiration for the six breathing cycles was calculated (Inspiration-Expiration
differences)13,14. During standing up, the program calculated the difference between the maximum
heart rate after the manoeuvre and control heart rate (mean of 30 seconds) before (delta maximum
heart rate) and also the quotient of maximum heart rate and minimum heart rate after standing up
(T/B ratio). Furthermore, the difference in averaged diastolic blood pressure between 50 and 80 sec-
onds in the standing position and during the control supine period is calculated (delta diastolic blood
pressure).The highest Valsalva ratio of the three manoeuvres, defined by the lowest heart rate after the
manoeuvre, was used to evaluate the heart rate variability during this test. During sustained handgrip,
the highest increase in average diastolic blood pressure over 5 seconds (delta diastolic bloodpressure)
was calculated.The results were defined as abnormal if the test parameter was below the 5th percentile
of normal. During the standing up test, heart rate variability was abnormal if delta maximal heart rate
and T/B ratio were below the 5th percentile. Cardiovascular AN was defined as abnormal if 2 or more
of the 5 test parameters were abnormal, because of poor predictive value of a single test parameter3,15.
The basal plasma PP level was taken as the mean of two unstimulated samples obtained with a 5
minute interval after an overnight fast of at least 12 hours.The integrated incremental PP response was
determined by calculating the area under the plasma PP concentration-time curve after subtraction of
the mean baseline value.
Statistical analysis was performed by analysis of covariance after logarithmic transformation with
age as a covariate and by the rank sum test.Two tailed p values were calculated. Results are given as
median and range, unless stated otherwise.The study was approved by the local ethics committee, and
all subjects gave their informed consent.
Results
Plasma PP concentration-time curves after intravenous stimulation with 0.4 mg/kg.15min of ERY,
1.2 mg/kg.15min of ERY or MSF are depicted in figures 1, 2 and 3, respectively. Mean basaline PP
levels before stimulation with ERY, were decreased (p<0.05) in group A when compared to group B
(27 [16-94] and 40 [25-149] pM, respectively; figure 4).The integrated plasma PP response in group
A, after stimulation with 0.4 mg/kg.15min of ERY, was lower than in group B (509 [121-2290]
pM*20min vs 1021 [326-2964] pM*20min, respectively), but this difference just failed to reach sta-
tistical significance (p<0.1; figure 5). However, after stimulation with 1.2 mg/kg.15min of ERY, inte-
grated plasma PP responses in group A (776 [29-2670] pM*20min) were significantly decreased
(p<0.05), compared to group B (1228 [514-7608] pM*20min)(figure 6).Analysis of covariance of PP
responses with age as a covariate, revealed a significant (p=0.06) age effect and the differences between
group A and B became even more apparent and significant for stimulation with both doses of ERY
(p=0.05 for the 0.4 mg/kg.15min dose and p=0.007 for the 1.2 mg/kg.15min dose). In 5 patients of
group A, the integrated PP response to 1.2 mg/kg.15min of ERY was below the lowest value in group
B, but only in 2 patients of group A after 0.4 mg/kg.15min of ERY.The integrated PP response to
MSF in group A was not significantly different (923 [65-4505] pM*60min) from group B (1580 [473-
5115] pM*60min;p=0.3) (figure 7). In 3 patients of group A, the integrated PP response to MSF was
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Fig 1: Delta PP time curves after stimulation with 0.4
mg/kg.15min ERY (i.v.) in 11 patients with chronic
liver disease (group A; closed dots) and 20 controls
(group B; open dots).
Fig 2: Delta PP time curves after stimulation with 1.2
mg/kg.15min ERY (i.v.) in 11 patients with chronic
liver disease (group A; closed dots) and 20 controls
(group B; open dots).
Fig 3: Delta PP time curves after stimulation with
MSF in 11 patients with chronic liver disease (group
A; closed dots) and 8 controls (group B; open dots).
1
3
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below the lowest value of group B. In one patient
of group B (F; 55 years), plasma CCK levels in re-
sponse to MSF exceeded baseline levels by more
than 1.3 pM suggesting swallowing of food16. For
this reason she was excluded from this part of the
study. In non of the other subjects of group A or
B, CCK plasma levels exceeded baseline levels.
Integrated plasma PP levels of the intestinal phase
of the meal (30-40 min) were not significantly
different between groups A and B (755 [185-
2800] pM*10min and 855 [-20-5595]
pM*10min, respectively).
Integrated PP-responses to ERY or MSF in
sclerotherapy patients, were not different from
non-sclerotherapy patients. Four (36%) of the pa-
tients with chronic liver disease (2 child A; 2
Child B) had an abnormal Finapres response. In-
tegrated PP responses in the patients with cardio-
vascular AN were 598 [359-1463] pM*20min,
1050 [29-2238] pM*20min and 2149 [145-3405]
pM*60min, after stimulation with 0.4 mg/
kg.15min of ERY, 1.2 mg/kg.15min of ERY and
MSF, respectively. These PP responses were not
significantly different from the values obtained in the patients with a normal cardiovascular reflex test
(459 [121-2290] pM*20min, 430 [170-2670] pM*20min and 770 [65-4505] pM*60min, respective-
ly).
Discussion
In the present study we have demonstrated that patients with chronic liver disease mainly classified
as Child A,had a significantly lower PP response to intravenous ERY than age matched controls. Since
ERY induced PP release is dependent on an intact vagal cholinergic nerve supply and since it has been
demonstrated that patients with chronic liver disease may have vagal nerve damage as a consequence
of AN1,2,17,18, our data may suggest that an impaired PP response to intravenous ERY reflects dysfunc-
tion of the vagal nervous system in patients with chronic liver disease. MSF as a test for the evaluation
of vagal nerve integrity, did not reveal significant differences in PP response between patients with
chronic liver disease and controls. Several studies have claimed that the PP response to MSF is safe and
reliable to test vagal nerve integrity, because PP release to the cephalic phase of a meal is dependent
on intact long vagal cholinergic pathways19,20,21,22. If performed properly, without swallowing any food,
the PP response to MSF is specific but the sensitivity of the test to determine vagal cholinergic nerve
integrity is rather low, because of low PP responses in normal subjects. In our MSF study one patient
with a rise in plasma CCK concentration suggesting inadvertent swallowing of food was excluded
59
Fig 4: Basal individual plasma PP levels in 11 pa-
tients with chronic liver disease (group A; closed dots)
and 20 controls (group B; open dots).
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Fig 5: Integrated plasma PP responses over a 20
minute interval after stimulation with 0.4
mg/kg.15min (i.v) in 11 patients with chronic liver
disease (group A; closed dots) and 20 controls (group
B; open dots).
Fig 6: Integrated plasma PP responses over a 20
minute interval after stimulation with 1.2
mg/kg.15min (i.v) in 11 patients with chronic liver
disease (group A; closed dots) and 20 controls (group
B; open dots).
Fig 7: Integrated plasma PP responses over a 60
minute interval after stimulation with MSF in 11 pa-
tients with chronic liver disease (group A; closed dots)
and 8 controls (group B; open dots).
5 6
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from this part of the study16.The lack of differences in MSF stimulated PP release between patients
with chronic liver disease and controls may on the one hand be the result of the low sensitivity of the
test, but on the other hand be related to the stage of chronic liver disease in our patients, since the ma-
jority of our patients with chronic liver disease were classified as Child A.The PP response to insulin
induced hypoglycaemia is probably the most appropriate test to assess vagal nerve function5,23,24. How-
ever, we did not perform this test in our patients with liver disease, since stimulation of PP release by
insulin induced hypoglycaemia may be hazardous in such patients due to the risk of prolonged hypo-
glycaemia25.
The cardio-vascular responsiveness to standardized manoeuvres, may be diminished in patients
with chronic liver disease1,2,17,18. However, even if multiple cardiovascular reflex tests are used for the
evaluation of the autonomic nervous system, it is uncertain if these tests adequately assess autonomic
nerve function of the gastrointestinal tract, since damage to peripheral, sympathetic, and parasympa-
thetic nerves may occur independently of one another2.
In the present study 5 of the 11 patients with chronic liver disease had an abnormal PP response to
ERY, and 4 of the 11 patients had an abnormal test result with the Finapres computer program. How-
ever, only one of the patients scored abnormal in both tests, indicating a poor relation between the PP
response to ERY and the Finapres results.Therefore, it is suggested that gastrointestinal autonomic
dysfunction may occur independent of cardiovascular autonomic dysfunction in patients with chron-
ic liver disease.Vagal dysfunction of the cardiovascular system in patients with chronic liver disease
identifies a subgroup of patients with a substantial dismal outlook1.The clinical implication of an ab-
normal PP response to ERY remains to be established.
The integrated PP release after ingestion of a meal was prominent, demonstrating that PP cells were
intact and capable to release PP irrespective of AN in patients and controls.The difference in ERY
stimulated PP response between groups A and B is therefore not explained by PP cell damage.
Baseline and stimulated plasma PP levels may increase progressively with age26,27.Therefore, we per-
formed analysis of covariance on the data with age as a covariate. Correction for age resulted in even
more pronounced differences between groups.
Decreased baseline PP levels have been reported in patients with obesity and autonomic neu-
ropathy28,29.The significantly lower mean baseline PP levels in our patient group seem to be the re-
sult of AN, since no differences in Quetelet indexes were found between patients and controls.Yet,
the baseline PP values were less discriminative than ERY stimulated PP values in our study, be-
cause the overlap between patients and controls was greater for baseline PP than for ERY stimulated
values.
In conclusion, the present study demonstrates that integrated PP release in response to intravenous
administration of ERY, is decreased in patients with chronic liver disease classified as Child A or B.The
decreased PP response to ERY most probably reflects vagal-cholinergic nerve dysfunction,which may
indicate AN of the gastrointestinal tract.
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Abstract
Pancreatic polypeptide release in response to intravenously administered erythromycin is depen-
dent on intact vagal cholinergic pathways and requires an intact antrum. Since autonomic neuropathy
of the gastrointestinal tract damages vagal nerve integrity and frequently complicates the course of di-
abetes mellitus, we have studied the pancreatic polypeptide response to erythromycin in 17 diabetics
with abnormal cardiovascular reflex tests and with (n=8) or without (n=9) symptoms suspicious of
autonomic neuropathy of the gastrointestinal tract. Age matched controls with atypical abdominal
complaints (n=20) and patients with surgical vagal nerve damage (n=4) were also studied.The inte-
grated pancreatic polypeptide responses to erythromycin were significantly lower in diabetics with
gastrointestinal symptoms and in patients with surgical vagal damage, when compared to controls and
diabetics without gastrointestinal complaints.
We conclude that in diabetics with complaints suspicious of gastrointestinal autonomic neuropathy,
erythromycin stimulated pancreatic polypeptide release is decreased. It is speculated that this impaired
pancreatic polypeptide response to erythromycin reflects autonomic neuropathy of the gastrointesti-
nal tract.
Introduction
Diabetes mellitus is frequently complicated by autonomic neuropathy, which may affect virtually
all systems including the gastrointestinal tract.The late clinical manifestations of autonomic neuropa-
thy are hypoglycaemic unawareness, spontaneous cardiac arrest and silent myocardial infarction1,2.Gas-
trointestinal manifestations of autonomic neuropathy are quite common and include constipation,
anorexia, nausea, vomiting, early satiety, fullness, bloating, diarrhoea, anal incontinence and abdominal
pain3,4.
Presently, a combination of 5 simple, non-invasive cardiovascular reflex tests are used as “golden
standard” in the assessment of autonomic neuropathy5.These tests are developed to evaluate sympa-
thetic and parasympathetic autonomic nerve function of the cardiovascular system.Autonomic neu-
ropathy of the gastrointestinal tract can be investigated separately by testing the integrity of long va-
gal cholinergic pathways. This can be done by stimulating the vagal nuclei in the brain, either by
insulin-induced hypoglycaemia or by modified sham feeding6,7,8. In the presence of an intact efferent
vagal nerve system, these stimuli promote the release of pancreatic polypeptide (PP). It has been shown
that intravenously administered erythromycin (ERY) also stimulates PP release by cholinergic path-
ways9. In a recent study we have demonstrated that PP release to ERY is dependent on intact vagal
pathways10. It can therefore be speculated that ERY mediated PP release may be used to investigate va-
gal nerve integrity and to assess dysfunction of vagal cholinergic pathways as a consequence of auto-
nomic neuropathy in patients with diabetes mellitus.
To test this hypothesis, we have studied the plasma PP response to ERY in diabetes mellitus with
abnormal cardiovascular reflex tests with or without gastrointestinal symptoms suspicious of auto-
nomic neuropathy of the gastrointestinal tract and we have compared the results of ERY stimulated
PP release with those obtained in age matched controls and in patients with proven surgical vagal
nerve damage.
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Patients and methods
The PP response to intravenous stimulation with 0.4 mg/kg.15 min and 1.2 mg/kg.15 min of
ERY was measured in 17 diabetes mellitus patients (group A; 9F; 8M; median age 60 [30-79] yrs), in
4 patients with surgical vagal nerve damage (group B; 4M; median age 49 [28-68] yrs) and in 20 con-
trols with abdominal complaints that fulfilled the exclusion criteria (group C; 9F; 11M; median age 45
[21-71] yrs). Eight of these controls met the criteria for irritable bowel syndrome, 4 had proctitis and
3 had Crohn’s disease (all in remission), 4 had non ulcer dyspepsia and one had colonic polyps.The
characteristics of the diabetes mellitus patients are shown in table 1.Three patients in group B had an
accidental vagotomy after anti-reflux surgery and 1 patient had truncal vagotomy for peptic ulcer dis-
ease.Vagal nerve dysfunction in these patients was demonstrated by reduced PP release in response to
insulin-induced hypoglycaemia (plasma glucose <2.5 mmol/l; incremental PP < 50 pM)11,12,13,14. Pa-
tients with chronic liver disease, alcohol abuse, previous upper abdominal surgery, neurological disease,
pancreatic insufficiency, heart disease, hypertension, irregular heart rate or patients on medication
known to affect the autonomic nervous system were excluded from the study. Polyneuropathy was as-
sessed by clinical signs and symptoms and diothesiometry (Biomedical Instruments).
After an overnight fast, blood samples for PP and glucose were taken at 5 min intervals twice be-
fore and at +5,+10,+15,+20,+30, and +60 min during and after stimulation with 0.4 mg/kg.15 min
and 1.2 mg/kg.15 min of ERY, respectively. Before the tests, blood was drawn to determine HbA1c
levels.The patients were asked to take 50% of the prescribed dose of insulin.At the end of the test, the
other 50% of the insulin dose was injected.
The cardiovascular reflex tests included 3 parasympathetic and 2 sympathetic tests.The parasympa-
thetic tests were heart rate variation with deep breathing, supine/erect heart rate and Valsalva ratio,
while the sympathetic tests were postural adjustment ratio and sustained handgrip. In one diabetes
mellitus patient (M;57 yrs) the cardiovascular reflex test were performed in the classical way. In all oth-
er diabetes mellitus patients, the test results were monitored using the FINger Arterial PRESsure
method (FINAPRES)15.The principle of this instrument is based on servoplethysmomanometry, em-
ploying the volume clamp technique16,17.The finapres device (Finapres model 5;TNO,Amsterdam,The
68
Table 1: Characteristics of diabetes mellitus patients. N.P. = nefropathy; R.P. = retinopathy; P.N. =polyneu-
ropathy;T.T.S = total symptom score.
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Netherlands) was connected to an IBM-compatible computer using normal co-axial or shielded ca-
ble with a standard BNC connector. In Turbopascal 3.0 (Borland International Inc, Scotts Valley, CA,
U.S.A.) a programme was written based on a timeclock. Before each test the clock was started and the
recorded digital signal of the finapres was used to calculate the programmed test results.The manoeu-
vres were performed after rest and in the posture described by Wieling and co-workers18. Before the
start of the test, the subjects were trained to perform the manoeuvres correctly.The finapres cuff was
wrapped around the middle finger of the non-dominant arm, which was fixed exactly at heart level.
Each subject refrained from smoking and caffeine- or alcohol-containing beverages for 12 hours be-
fore the test. Control systolic blood pressure, diastolic blood pressure, mean blood pressure and heart
rate were calculated as the mean values during the 30 s before the onset of each manoeuvre. Cardio-
vascular autonomic neuropathy was defined as an abnormal score of 2 or more of the 5 tests15.
For the assessment of gastrointestinal symptoms, all diabetes mellitus patients were asked to keep a
daily symptom score record list for one week. The total symptom score (TSS) was assigned to the
severity and frequency of pyrosis, nausea, vomiting, ructus, fullness, bloating and retrosternal or ab-
dominal pain using a scale from 0 to 3 (0 = absence of symptoms; 1 = mild symptoms noticed only
when payed attention to; 2 = moderate, symptoms clearly noticed only without interfering with nor-
mal daily activities; 3 = severe, symptoms interfering with normal daily activities)19. Based on the to-
tal symptom score patients with diabetes mellitus were subdivided in group A1 (a score of > 10) and
group A2 (a score of £ 10).A cumulative symptom score above 10 was considered abnormal. Other
possible causes related to the symptoms like pyrosis, nausea, vomiting, ructus, fullness, bloating and ret-
rosternal or abdominal pain (e.g. reflux oesophagitis, peptic ulcer disease or gallstone disease) were ex-
cluded by upper abdominal endoscopy or ultrasonography.
Plasma PP was measured by a sensitive and specific radioimmunoassay as previously described20.The
basal plasma PP level was taken as the mean of two unstimulated samples. Integrated incremental PP
secretion was determined by calculation of the area under the plasma PP concentration-time curve af-
ter subtraction of mean basal values.All values are expressed as median and range, unless stated other-
wise. Statistical analysis was performed by Kruskal-Wallis one way analysis of variance and by the rank
sum test. In addition, integrated PP responses after logarithmic transformation were tested for signifi-
cance by analysis of covariance with age as a covariate.Two tailed probability (p) values were calculat-
ed.The study protocol was approved by the local ethics committee.All subjects gave their informed
consent to participate in the studies.
Results
One diabetes mellitus patient refused the 1.2 mg/kg.15 min ERY dose.All diabetics had 2 or more
abnormal finapres tests. Periferal neuropathy was detected in all but one of the diabetes mellitus pa-
tients (Table 1).
Basal PP levels of group A1 and B (19.5 [9-48] pM and 27.5 [20-56] pM, respectively) were lower
than those of group A2 and C (57 [23-111] pM and 54 [22-122] pM, respectively).
The delta PP concentration-time curves of the different groups are depicted in fig 1 and 2.The in-
tegrated PP responses to 0.4 and 1.2 mg/kg.15 min of ERY in group A (=A1 + A2) (629 [-81-2996]
pM*20min and 1307 [123-4365] pM*20min) were not significantly different from those of group C
(1021 [326-2964] pM*20min and 1228 [514-7608] pM*20min).After stimulation with 0.4 mg/kg.15
min of ERY, integrated PP responses in groups A1 and B (452 [-81-1513] pM*20min and 372.5 [184-
571]) were decreased (p<0.05) compared to groups A2 and C (1454 [321-2996] and 1021 [326-2964]
pM*20min, respectively) (fig 3).After stimulation with 1.2 mg/kg.15 min of ERY, integrated PP re-
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sponses in group A1 was also markedly (P<0.05) reduced (608 [123-1310] pM*20min) compared to
groups A2 and C (2233 [130-4365] and 1228 [514-7608] pM*20min, respectively) (fig 4).The inte-
grated PP response of group B (660.5 [276-1680]) was lower than that of group A2 and C but this dif-
ference was not statistically significant (p=0.1).Comparable differences between groups were obtained
when the data were tested by analysis of covariance with age as a covariate. Integrated plasma PP re-
sponses to both doses of ERY in groups A1 and B were not significantly different.
Mean HbA1c level in group A was 8.8 [6.1-11.8] mmol/l.There was no difference in HbA1c lev-
els between groups A1 and A2 (9.4 [7.5-11.8] mmol/l vs 7.9 [6.1-11.0] mmol/l).The diabetes melli-
tus patients had comparable blood glucose levels troughout the study, not exceeding 15 mmol/l. Pa-
tients with gastrointestinal symptoms suffered from diabetes mellitus for a median period of 33
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Fig 1: Delta PP concentration-time curves after intra-
venous stimulation with 0.4 mg/kg.15 min of ery-
thromycin in 8 diabetics with gastrointestinal symp-
toms (group A1; closed dots), in 9 diabetics without
gastrointestinal symptoms (group A2; open dots), in 4
patients with surgical vagal nerve damage (group B;
closed triangles) and in 20 controls (group C; open tri-
angles). Results are expressed as mean– SEM.
Fig 2: Delta PP concentration-time curves after intra-
venous stimulation with 1.2 mg/kg.15 min of ery-
thromycin in 7 diabetics with gastrointestinal symp-
toms (group A1; closed dots), in 9 diabetics without
gastrointestinal symptoms (group A2; open dots), in 4
patients with surgical vagal nerve damage (group B;
closed triangles) and in 20 controls (group C; open tri-
angles). Results are expressed as mean– SEM.
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[15-55] years, while those without these symptoms had diabetes mellitus for 28 [1-58] years (not sig-
nificant). Defaecation frequency was markedly lower (p<0.05) in the patients of group A1 (3 [0-18]
times/week) compared to those of group A2 (7 [3-25] times/week).
Discussion
In the present study we have demonstrated that the PP response to ERY is lower in diabetes melli-
tus patients with autonomic neuropathy and gastrointestinal symptoms than in controls and in diabetes
mellitus patients with autonomic neuropathy but without gastrointestinal symptoms. In previous stud-
ies it has been demonstrated that the PP response to ERY in healthy subjects is abolished by atropine9
and that ERY stimulated PP release is dependent on vagal nerve integrity10. Our data may therefore
indicate that stimulation of PP release by ERY may be used to assess vagal nerve integrity in diabet-
ics. Sensitive and specific tests to assess autonomic neuropathy of the gastrointestinal tract in diabetics
are needed, since the tests presently used, like the insulin-induced hypoglycaemia test and the sham
feeding test, are potentially dangerous and difficult to perform in diabetics or are not sensitive enough.
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Fig 3: Integrated plasma PP responses over a 20
minute interval after intravenous stimulation with 0.4
mg/kg.15 min of erythromycin in 8 diabetics with gas-
trointestinal symptoms (group A1; closed dots), in 9 di-
abetics without gastrointestinal symptoms (group A2;
open dots), in 4 patients with surgical vagal nerve dam-
age (group B; closed triangles) and in 20 controls
(group C; open triangles). Results are expressed as
mean– SEM.
Fig 4: Integrated plasma PP responses over a 20
minute interval after intravenous stimulation with 1.2
mg/kg.15 min of erythromycin in 7 diabetics with gas-
trointestinal symptoms (group A1; closed dots), in 9 di-
abetics without gastrointestinal symptoms (group A2;
open dots), in 4 patients with surgical vagal nerve dam-
age (group B; closed triangles) and in 20 controls
(group C; open triangles). Results are expressed as
mean– SEM.
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Based on abnormal PP responses to insulin induced hypoglycaemia in patients with normal car-
diovascular reflex tests, it has been suggested that gastrointestinal autonomic neuropathy precedes car-
diovascular neuropathy13,21,22. In our study all diabetes mellitus patients had autonomic neuropathy as
assessed by cardiovascular reflex tests. However, only a subgroup of these patients had a decreased PP
response to ERY.This suggests that cardiovascular reflex tests may either have a higher sensitivity to
detect autonomic neuropathy than the ERY test, or that cardiovascular autonomic neuropathy pre-
cedes gastrointestinal autonomic neuropathy or that it occurs independently in diabetes mellitus pa-
tients.The correlation between ERY stimulated PP release and dyspeptic symptoms suggests that car-
diovascular autonomic neuropathy precedes intestinal autonomic neuropathy or develops
independently in our diabetes mellitus patients.
PP release is influenced by plasma glucose levels23,24,25.To minimize the effect of this factor, the pa-
tients were restrained from eating for 15 h prior to the tests, and blood glucose levels were measured
at regular intervals during the tests. Blood glucose levels in our diabetes mellitus patient group ranged
from 7 to 14 mmol/l,without differences between the patients with or without gastrointestinal symp-
toms.This excludes the possibility that the decrease of ERY stimulated PP release in diabetes mellitus
patients with gastrointestinal symptoms was the result of hyperglycaemia25.
Jebbink et al have demonstrated that dysregulation and hyperactivity of the small intestine are ear-
ly manifestations in diabetics with cardiac autonomic neuropathy19.Analogous to ERY stimulated PP
release, these motor abnormalities correlated with gastrointestinal symptoms but not with the severi-
ty of cardiac autonomic neuropathy as assessed by standard cardiovascular reflex tests19.When com-
pared to ERY stimulated PP release, the assessment of gastrointestinal motor disorders is difficult, time
consuming and requires expertise.
Diarrhoea may be an important gastrointestinal problem in long standing diabetes mellitus and its
prevalence has been underestimated4,26.On the other hand, constipation is one of the most bothersome
gastrointestinal complaints in diabetics and appears to be related to parasympathetic autonomic neu-
ropathy27,28. Chang et al postulated that diarrhoea in diabetics might be due to reduced electrolyte ab-
sorption, secondary to loss of normal sympathetic innervation29,30. In our diabetes mellitus patient
group, constipation but not diarrhoea was a major problem.The diabetes mellitus patients with gas-
trointestinal symptoms had a significantly lower defaecation frequency than those without gastroin-
testinal symptoms.This suggests that in our patient group, autonomic neuropathy of the gastrointesti-
nal parasympathetic system was more pronounced than autonomic neuropathy of the sympathetic
system.
In interpreting ERY stimulated PP release, one must take into account that PP release is influenced
by several disturbing factors, like age, circadian rhythm, obesity, pancreatic insufficiency, duodenal ul-
cer disease, stressful events and renal insufficiency20,31,32,33,34. In 4 diabetes mellitus patients with protein-
uria, basal and stimulated PP levels did not differ from the other patients (results not shown). Further-
more, similar results were obtained when differences between groups were tested by analysis of
covariance with age as a covariate. Obesity, duodenal ulcer disease, alterations induced by circadian
rhythm and pancreatic insufficiency were also excluded as confounding factors in the present study.
We conclude that ERY stimulated PP release in diabetes mellitus patients is decreased in a sub-
group of patients with gastrointestinal symptoms, suggesting that a decreased PP response to ERY re-
flects the presence of gastro-intestinal autonomic neuropathy. It is tempting to speculate that the PP
response to ERY may be used to assess autonomic neuropathy of the gastrointestinal tract in diabet-
ics.
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Abstract
In order to assess vagal nerve integrity, we have studied pancreatic polypeptide responses to insulin
induced hypoglycaemia in Parkinson’s disease patients, with (group A1, n=7) or without (group A2,
n=12) levodopa treatment and in 8 controls (group B). Patients kept a diary for one week to reveal
symptoms suggestive of gastrointestinal autonomic dysfunction. Cardiovascular reflex tests were also
performed. Integrated PP release in response to insulin hypoglycaemia was decreased in both, group A1
(4390 [1025-8400] pM*30min) and group A2 (4362 [935-9465] pM*30min) compared to group B
(8587 [5205-18550] pM*30min; p<0.05). Integrated PP response to insulin induced hypoglycaemia
was significantly lower in patients with abnormal results of cardiovascular reflex tests (p<0.05) and ab-
normal gastrointestinal symptom score (p<0.05) when compared to patients with normal results.
Conclusion. Pancreatic polypeptide responses to insulin induced hypoglycaemia are decreased in
Parkinson patients. Decreased pancreatic polypeptide responses in these patients are related to abnor-
mal cardiovascular reflex tests and symptoms suggestive of gastrointestinal autonomic neuropathy.
Introduction
Neuropathy frequently complicates the course of Parkinson’s disease1-6. In this process, damage to
peripheral, sympathetic or parasympathetic nerves may occur independently of one another7-9. It is
generally accepted that assessment of autonomic neuropathy should be based on a series of distinct
tests, rather than on a single investigation of one reflex system. Recently, an automated program was
developed, using a finapres device and a personal computer, to perform five cardiovascular reflex tests
for the assessment of cardiovascular autonomic neuropathy in a simple and quick way10-12. Cardiovas-
cular reflex tests are presently considered as the “golden standard” in the assessment of autonomic neu-
ropathy13,14. In addition, several tests have been described to evaluate vagal nerve integrity of the gas-
trointestinal tract.The release of pancreatic polypeptide (PP) plays a key role in these tests because this
hormone is completely under vagal cholinergic control15. Impaired PP secretion can therefore be used
as a sensitive indicator for autonomic nerve dysfunction of the gastrointestinal system. Stimulation of
vagal cholinergic pathways can be achieved by insulin induced hypoglycaemia, modified sham feed-
ing or electrical stimulation of the vagal nerve15.
Most patients with Parkinson’s disease are allocated to treatment with levodopa. Dopamine may
decrease basal PP concentration and inhibit postprandial PP release in men via dopaminergic and
adrenergic receptors16,17.The extensive dopaminergic innervation of the upper gastrointestinal tract18 as
well as the uptake and decarboxylation of levodopa by PP-producing cells19 suggests that this mecha-
nism may be of biological importance.The effect of levodopa on PP release in response to insulin in-
duced hypoglycaemia is presently not known.
The aim of this study was to determine whether PP responses to insulin induced hypoglycaemia
are disturbed in patients with Parkinson’s disease.A second aim was to determine whether a relation-
ship exists between PP responses to insulin induced hypoglycaemia and abnormal cardiovascular re-
flex tests and symptoms suggestive of gastrointestinal autonomic dysfunction.
Patients
Nineteen ambulant patients (group A: 7F, 12M;median age 54 [39-79] yrs) with Parkinson’s disease
according to the criteria of the UK Parkinson’s Disease Society Brain Bank and 8 ambulant control
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patients on treatment for abdominal complaints (group B: 5F, 3M; median age 37.5 [22-59] yrs) were
studied.Characteristics of the Parkinson’s disease patients are depicted in table 1. Five of the control pa-
tients met the criteria of irritable bowel syndrome. One had lymphangiectasia of the small bowel, one
had proctitis, one had an extirpation of the spleen due to a traumatic rupture and one had unilateral
paralysis of the diaphragma of unknown origin. Median body weight and length of the patients of
group A and the control subjects of group B were 74 [57-104] kg/174 [157-188] cm and 69 [48-115]
kg/169 [164-178] cm, respectively. In group A, the stages of Parkinson’s disease according to Hoehn &
Yahr were I in 7, II in 4, III in 6 and IV in 2 patients. Seven patients with Parkinson’s disease used levo-
dopa 400-700mg/24hr (with decarboxylase inhibitor) until 10 hours before the tests (group A1:2F,5M;
median age 68 [47-79] yrs).All other Parkinson’s disease patients (group A2:5F,7M;median age 49 [39-
65] yrs) used no medication (n=9) or discontinued their medication for more than 5 days before the
tests (n=3). None of the patients or controls used anticholinergic medication or other medication
known to affect PP responses. Patients with diabetes mellitus, recent alcohol abuse, oesophago-gastric
surgery, other neurological disorders, cardiovascular disease or other factors that could influence test re-
sults, were excluded from the study. One patient with Parkinson’s disease was excluded (M, 56 yrs) be-
cause of insufficient insulin induced hypoglycaemia (defined as < 2.5 mmol/L).
Methods
All tests were performed after an overnight fast. Blood samples for PP and glucose were taken in
the fasting state and at 10 minute intervals for one hour after the intravenous administration of insulin
(0,1 IU/kg).
To show that PP cells were intact and capable of producing the hormone, a standardized meal con-
sisting of 2 slices of buttered bread with 50 gr of cheese, a boiled egg and 200cc tea with 10 gr of su-
gar, was ingested over a 20 minute period and blood samples for PP were obtained at 10 minute in-
tervals after taking two unstimulated samples.
In addition 5 cardiovascular reflex tests were performed in all patients with Parkinson’s disease.
During these tests, a finapres (FINger Arterial PRESsure) device recorded heart rate (beats/min) and
blood pressure (mmHg) continuously from a finger.The principle of this instrument is based on ser-
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Table 1: Data and characteristics of all Parkinson’s disease patients.
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voplethysmomanometry, employing the volume clamp technique10,11.The digital signal of the Finapres
was recorded by a personal computer. Immediately after the tests were performed, a special developed
computer programme calculated the test results automatically. The finapres cuff (Finapres model 5
TNO, Amsterdam, The Netherlands) was wrapped around the middle finger of the non-dominant
hand, and was fixed at heart level. Before starting the tests the manoeuvres were trained to perform
them correctly, according to the timeclock of the computer programme.
After 5 minutes of supine rest, the subjects performed six consecutive maximal respirations in 1
minute. Five minutes later the subjects stood up and remained in the upright position for 2 minutes.
After 2 minutes rest in the sitting position the Valsalva manoeuvre was performed three times, each af-
ter 1 minute rest. Finally the patients were asked to exert 30% of their previously determined maxi-
mum voluntary contraction for 3 minutes on a handgrip dynameter, 2 minutes after the last Valsalva
manoeuvre.
During deep breathing at 6 breaths/min, the mean difference between the highest heart rate in in-
spiration and the lowest in expiration for six consecutive breathing cycles was calculated12. During the
standing up test, the programme calculated the difference between the maximum heart rate after the
manoeuvre and the control heart rate before and the quotient of maximum heart rate and minimum
heart rate after standing up20. Furthermore, the difference in averaged diastolic blood pressure between
50 and 80 seconds in the standing position and during the control period was calculated21.The high-
est Valsalva ratio of the three manoeuvres performed, stated the maximum heart rate variability dur-
ing this test22. During sustained handgrip the highest increase in average diastolic blood pressure over
5 seconds was calculated.The test results were interpreted as abnormal if the testparameter was below
the 5th percentiles of normal12.Autonomic neuropathy was defined as an abnormal score of 2 or more
of the 5 tests12.
For the assessment of bowel movement frequency and gastro-intestinal symptoms, all Parkinson’s
disease patients were asked to keep a daily symptom score record list for a week23. Constipation was
defined as a bowel movement of £ 5/week.The total symptom score included symptoms like pyrosis,
nausea, vomiting, ructus, fullness, bloating and retrosternal or upper abdominal pain using a scale from
0 to 3 (0 = absence of symptoms; 1 = mild, symptoms noticed only when payed attention to; 2 =
moderate, symptoms clearly noticed only without interfering with normal daily activities; 3 = severe,
symptoms interfering with normal daily activities).A cumulative symptom score above 10 was con-
sidered abnormal.
Plasma PP was measured by a sensitive and specific radioimmunoassay24.All values are reported as
median and range. Plasma PP concentrations obtained at 30, 40, 50 and 60 minutes were used to de-
termine integrated PP response to insulin.This integrated PP response was determined by calculating
the area under the curve after subtraction of the baseline values.
Statistical analysis was performed by Kruskal Wallis one way analysis of variance followed by the
rank sum test.All tests were two tailed.A difference was considered to be statistically significant if p-
values were equal to or below 0.05.The study was approved by the local ethics committee and all sub-
jects gave their informed consent to participate in the studies.
Results
In all Parkinson patients that participated in the study, the PP cells were intact and capable of pro-
ducing PP as demonstrated by an incremental PP release of more than 50 pM after the ingestion of a
test meal15. In the control subjects the individual delta PP after stimulation with insulin hypoglycaemia
always exceeded 250 pM.
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The basal plasma PP levels of group A2 (21 [9-47] pM) but not those of group A1 (37 [11-83])
were lower (p=0.01) than those of group B (49 [21-110]). Basal PP concentrations were equivalent or
below the lowest value in the control group B in 1 of the patients of group A1 and in 7 of the patients
of group A2. Individual basal plasma PP levels are shown in figure 1.
After insulin induced hypoglycaemia, the integrated PP response in the patients of group A1 and
group A2 were decreased (4390 [1025-8400] pM*30min, p=0.04 and 4362 [935-9465] pM*30min,
p=0.006 respectively) compared to that of group B (8587 [5205-18550] pM*30min).
The integrated PP response to insulin induced hypoglycaemia of the Parkinson patients classified
as stage I or II (N=11) and those classified as III or IV (N=8) according to Hoehn & Yahr were not
statistically different from each other (4675 [975-8400] pM*30min and 3790 [935-9465] pM*30min,
respectively).
Individual insulin stimulated plasma PP peak increments of group A1,A2 and B are depicted in fig-
ure 2.The peak incremental PP response to insulin induced hypoglycaemia was markedly decreased
in the patients of group A1 (168 [86-373] pM; p=0.02) and group A2 (199 [82-446] pM; p=0.02)
compared to the subjects of group B (335 [261-920] pM).The peak incremental PP response to in-
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Fig 1: Individual basal plasma PP levels in 7 Parkin-
son patients on levodopa treatment (group A1: closed
dots), 12 Parkinson patients without levodopa treat-
ment (group A2: open dots) and 8 controls (group B:
crosses).
Fig 2: Individual incremental plasma PP levels after
intravenous stimulation with insulin (0,1 IU/kg as a
bolus) in 7 Parkinson patients on levodopa treatment
(group A1: closed dots), 12 Parkinson patients without
levodopa treatment (group A2: open dots) and 8 con-
trols (group B: crosses).
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sulin induced hypoglycaemia was below the lowest value in the control subjects of group B in 5 of the
patients of group A1 and in 8 of the patients of group A2. Basal and insulin stimulated PP were not
significantly different among group A1 and A2 patients with Parkinson’s disease.
All patients with Parkinson’s disease that participated in the study even those with severe rigidity
or tremor of the hands were able to perform the Finapres tests correctly. In 10 of the 19 Parkinson pa-
tients the cardiovascular reflex tests were abnormal (2 in group A1 and 8 in group A2). Integrated PP
response to insulin induced hypoglycaemia was decreased (p=0.02) in these Parkinson patients (2667
[935-8130] pM*30min) compared to the Parkinson patients with normal cardiovascular reflex tests
(6580 [3625-9465] pM*30min).
In the Parkinson patients with a bowel movement of £ 5/week (n=8), the integrated PP response
to insulin hypoglycaemia was not significantly decreased (3272 [975-9465] pM*30min; p=0.3) com-
pared to the Parkinson patients with bowel movements of more than 5 times a week (n=11; 4835
[935-8400] pM*30min). Four of the Parkinson patients of group A1 and 6 of the patients of group A2
had a symptom score of ‡ 10. In the Parkinson patients with a total symptom score of ‡ 10, the inte-
grated PP release to insulin induced hypoglycaemia was significantly (p=0.006) decreased (3185 [935-
6580] pM*30min) when compared to Parkinson patients with a lower total symptom score (6825
[2590-9465] pM*30min).
Discussion
In previous experiments it was demonstrated that the PP response to insulin induced hypogly-
caemia is a sensitive and specific marker for vagal dysfunction, for instance in case of autonomic neu-
ropathy, provided that PP producing cells in the pancreas are intact15,25. Since autonomic neuropathy
may frequently complicate the course of Parkinson’s disease, we have performed the present study.We
have related the results with a symptom score for autonomic gastrointestinal neuropathy and with car-
diovascular reflex tests.
In the present study the PP response to insulin induced hypoglycaemia was significantly decreased
in patients with Parkinson’s disease when compared to controls.The differences in PP responses to in-
sulin induced hypoglycaemia between controls and Parkinson patients could not be explained by
treatment with levodopa. In previous studies it was demonstrated that dopamine decreased basal plas-
ma PP concentrations and inhibited postprandial PP release in humans16,17. In our study, however, no
difference in basal and integrated PP response to insulin induced hypoglycaemia was observed be-
tween Parkinson patients with or without levodopa. On the one hand, this may be explained by dis-
continuation of levodopa administration for at least 10 hours before the experiments in our study. On
the other hand one may speculate that levodopa treatment has only little effect on PP response after
insulin hypoglycaemia.
In previous studies it has been demonstrated that the PP response to insulin induced hypoglycaemia
is more sensitive to detect autonomic neuropathy than basal PP levels15,26. In the present experiment,
basal PP levels and the PP response to insulin induced hypoglycaemia were lower in Parkinson pa-
tients compared to controls. However, the overlap in basal PP levels between controls and patients was
more pronounced than the overlap in PP responses to insulin induced hypoglycaemia.This supports
previous findings that the PP response to insulin induced hypoglycaemia is probably a more sensitive
marker to detect autonomic neuropathy than basal PP levels15.
A significant negative relation between PP responses to insulin induced hypoglycaemia and the
severity of gastrointestinal symptoms in Parkinson patients was observed. However, no significant re-
lation was found between the PP response to insulin induced hypoglycaemia and the severity of the
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disease as indicated by the Hoehn & Yahr scale, indicating that autonomic neuropathy may complicate
both, recent onset and advanced Parkinson’s disease4,27.
Presently, non-invasive cardiovascular reflex tests are used as “golden standard” to detect autonom-
ic neuropathy.A time consuming battery of cardiovascular reflex tests should be used because of the
poor predictive value of a single test parameter13.With the automated computerized programme used
in this study, the time required to elaborate all the test results can easily be overcome12. Furthermore,
all the Parkinson patients tested were able to perform the tests, even those with severe tremor and
rigidity. Satisfactory performance of these tests needs good co-operation and some of the tests are ef-
fort depending in these patients.
In clinical practice, the concordance between cardiovagal and abdominal vagal function tests re-
mains controversial28. In our study, the PP response to insulin induced hypoglycaemia was decreased
in Parkinson patients with abnormal cardiovascular reflex tests, or gastrointestinal symptoms.
Autonomic nerve function deteriorates with advancing age29,30. Basal and stimulated PP levels are
also related to age29,31.Therefore, it is important to take the age into account when evaluating PP re-
sults.The control group used in our studie was younger than our patient group. It may therefore be
suggested that the PP response after insulin hypoglycaemia in age matched controls could even be
more pronounced, resulting in more significant differences between the investigated groups.
We conclude that insulin stimulated pancreatic polypeptide release in Parkinson patients is de-
creased compared to controls.The results are not dependent on levodopa treatment.We speculate that
pancreatic polypeptide release in response to insulin induced hypoglycaemia may be helpful in the as-
sessment of gastrointestinal autonomic neuropathy in patients with Parkinson’s disease.
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Pancreatic polypeptide (PP) is a 36 amino-acid polypeptide localized in the secretory granules of
endocrine cells in the pancreas.The secretion of PP is affected by several physiological stimuli, such as
food intake and fluctuations in blood glucose concentrations.Vago-cholinergic mechanisms are in-
volved in the cephalic, gastric, intestinal and postabsorptive phase of digestion.The cephalic phase of
PP secretion, however, is selectively mediated by the vago-cholinergic system. For this special reason,
PP release after vagal-cholinergic stimulation by various stimuli can be used in the assessment of au-
tonomic neuropathy.
Modified sham feeding (MSF) has been demonstrated to activate central vagal activity resulting in
PP release.This PP response to MSF is modest and dependent on the quantity of food and the dura-
tion of MSF.Although gustatory, olphactory, acoustic and visual signals are known to be involved in
the cephalic phase of meal stimulation, no data were available on the stimulating effects of the differ-
ent components of food when sham fed. In chapter 2 we therefore investigated the contribution of
fat, protein and carbohydrates on the stimulation of vagal cholinergic activity on gallbladder contrac-
tion and in chapter 3 on PP release. Both,The gallbladder contraction and PP release in response to
MSF appeared to be dependent on the composition of the meal. Gallbladder contraction and PP re-
lease were mainly the result of the amount of fat or protein in the meals.The same nutrients that sti-
mulate gallbladder contraction during the intestinal phase also stimulate gallbladder contraction dur-
ing the cephalic phase of the meal, although via different mechanisms, since real feeding but not MSF
stimulates the release of CCK.There was a similar pattern of PP release in response to the cephalic and
intestinal phase of the meal. It seems that the same type of chemoreceptors are triggered by nutrients
throughout the intestine, but that the chemoreceptors subsequently may activate endocrine, or neu-
rocrine mechanisms depending on their location in the intestinal tract.
Erythromycin (ERY), stimulates PP release.This effect can be blocked by atropine but not by lox-
iglumide (a cholecystokinin antagonist), suggesting the importance of cholinergic pathways in this
process. It was not known whether the stimulation of PP cells by ERY is mediated centrally via the
vagal nerve or locally by gastroenteropancreatic cholinergic reflexes.To determine the role of long va-
gal and local gastropancreatic reflexes in ERY-induced PP release, ERY was administered as an intra-
venous bolus injection to healthy volunteers and patients with impaired vagal function with or with-
out gastric antrectomy.The results of this study, described in chapter 4, demonstrated that the effect of
ERY on PP release is to a large extent dependent on intact long vagal pathways.The diminished PP
response to ERY in vagotomized patients is further reduced by antrectomy, suggesting that ERY ac-
tivates both long vago-vagal and to a lesser extent local gastropancreatic cholinergic reflexes.
During the 1950s and 1960s clinical descriptions were made on autonomic neuropathy and phys-
iologists devised a variety of techniques to ascertain the patterns of autonomic nerve damage.This re-
sulted in a series of cardiovascular reflex tests.These tests exhibit both, symptoms and prognosis and it
can be assumed that cardiovascular reflex abnormalities indicate diffuse damage throughout the auto-
nomic nervous system. However, damage to peripheral, sympathetic and parasympathetic nerves may
occur independently of one another.
The release of PP to several different physiological stimuli can also be used in the assessment of 
autonomic neuropathy since the release of PP is selectively governed by vagal-cholinergic stimula-
tion. For this reason, the secretion of PP can be used for studies of vagal control of endocrine systems
at the afferent, central, and efferent levels of vago-vagal reflexes. In medical practice, stimulation of 
PP cells is achieved by sham feeding or acute insulin induced hypoglycaemia. Damage of the vago-
cholinergic axis may result in a decreased or absent PP response.Although sham feeding by the ‘chew
and spit’ technique is rather specific, it forms only a modest stimulation of vago-cholinergic acti-
vity resulting in approximately 20% negative results in normal subjects. Insulin induced hypogly-
caemia is a reliable method to test vagal nerve integrity.This test, however, is time consuming, haz-
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ardous and unpleasant for the patient. Furthermore, in diabetics, a rapid standardized hypoglycaemia is
difficult to achieve.
To investigate if ERY stimulated PP release could be of help in the assessment of gastrointestinal
autonomic neuropathy,we studied ERY stimulated PP release in patients with chronic liver disease (5)
and  diabetes mellitus (6) and insulin hypoglycaemia induced PP release in Parkinson’s disease (7).The
results of these tests were compared with cardiovascular reflex tests (5, 6 and 7) or MSF (5).We also
studied the  correlation between gastrointestinal symptoms and autonomic neuropathy as shown by
PP and cardiovascular reflex tests (6 and 7).
In patients with chronic liver disease, integrated PP response to ERY, but not to MSF was signifi-
cantly decreased compared to age matched patients with atypical abdominal complaints. Four of the
patients with chronic liver disease had abnormal cardiovascular reflex tests.The stimulated PP response
in these patients did not differ from those with normal cardiovascular reflex tests.
All patients with diabetes mellitus had abnormal cardiovascular reflex tests. In chapter 6 it was
demonstrated that the integrated PP release after stimulation with ERY is significantly decreased in
diabetics with complaints suspicious of gastrointestinal autonomic neuropathy and not in diabetics
without gastrointestinal complaints.
Integrated PP release after insulin hypoglycaemia was also decreased in patients with Parkinson’s
disease compared to age matched control patients with atypical abdominal complaints.The integrated
PP response to insulin hypoglycaemia was also decreased in Parkinson patients with abnormal cardio-
vascular reflex tests compared to those with normal cardiovascular reflex tests.The decreased PP test
results in Parkinson patients correlated with symptoms suspicious of gastrointestinal autonomic neu-
ropathy.
According to the results described in chapter 4,5,6 and 7, one may postulate that ERY stimulated
PP release may be a valuable, supplementary test in the assessment of gastrointestinal autonomic neu-
ropathy.
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Samenvatting
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Het autonome zenuwstelsel van het maag-darmkanaal is een multifunctioneel systeem dat de
motiliteit, de endo- en exocriene secretie en de microcirculatie coördineert.Het speelt ook een rol bij
de regulatie van immuun- en ontstekingsprocessen.
Pancreas polypeptide (PP) is een 36 aminozuren tellend polypeptide met hormonale eigenschap-
pen dat zich bevindt in de granula van de endocriene cellen in het pancreas. Deze zogenaamde “PP-
cellen” bevinden zich zowel in de eilandjes van Langerhans als tussen de acinaire cellen, hoofdzakelijk
in de kop van het pancreas. De secretie van PP wordt beïnvloed door verschillende fysiologische sti-
muli. Zo leidt eten tot een sterke stijging van de concentratie van PP in het bloed door een complexe
interactie tussen neurogene- en hormonale factoren.Tijdens de stimulatie van PP in de cephale fase
van een maaltijd speelt het vago-cholinerge systeem een essentiële rol. Zo kan de stimulatie van PP
tijdens deze fase volledig worden afgevlakt door het gelijktijdig toedienen van atropine, een anti-
cholinergicum. Hierdoor kan de toename van PP na stimulatie van het vago-cholinerge systeem een
bijdrage leveren aan de diagnostiek van diverse aandoeningen, waarbij stoornissen van het autonome
zenuwstelsel van het maag-darmkanaal, worden verondersteld. De cephale fase van de produktie van
PP wordt in de medische praktijk gestimuleerd door schijnvoeding of door insuline geïnduceerde hy-
poglycaemie.
Met schijnvoeding bedoelen we het laten ruiken en proeven van voedsel zonder dat dit mag wor-
den doorgeslikt. De PP-secretie na stimulatie met schijnvoeding is afhankelijk van de hoeveelheid
voedsel en de duur van de schijnvoeding.Verder is bekend dat smaak, geur, geluid en visuele factoren
een rol spelen bij de stimulatie van de cephale fase door schijnvoeding. Het is echter niet bekend wat
de invloed is van de samenstelling van de maaltijd die gebruikt wordt tijdens schijnvoeding. Daarom
hebben we in hoofdstuk 2 onderzocht wat het effect is van de hoeveelheid vet, eiwitten en koolhy-
draten in schijnvoeding op de vago-cholinerge stimulatie van de galblaascontractie en in hoofdstuk 3
op de PP-secretie. Zowel de galblaascontractie als de produktie van PP door schijnvoeding bleken
afhankelijk van de samenstelling van de maaltijd. Galblaascontractie en PP-secretie waren vooral
afhankelijk van de hoeveelheid vet en eiwit in de schijnvoeding. Dezelfde voedingsstoffen die de gal-
blaascontractie stimuleerden tijdens de intestinale fase stimuleerden ook de galblaascontractie tijdens
de cephale fase van de maaltijd. Dit gebeurt echter via verschillende mechanismen omdat schijnvoed-
ing in tegenstelling tot doorslikken van voeding geen toename teweeg brengt van het hormoon
cholecystokinine. Er was eenzelfde patroon in de concentratie-tijd curve herkenbaar tijdens de stim-
ulatie van PP in de cephale en intestinale fase van de verschillend samengestelde maaltijden. Mogelijk
dat dezelfde chemoreceptoren door het gehele maag-darmstelsel actief zijn, maar afhankelijk van de
locatie in het maag-darmstelsel endocriene-, paracriene- of neurocriene mechanismen stimuleren.
Erythromycine (ERY), een antibioticum uit de macrolide-groep stimuleert de produktie van PP.
Deze stimulatie kan worden geblokkeerd door atropine, maar niet door loxiglumide (een cholecys-
tokinine antagonist). Dit geeft het belang aan van het cholinerge systeem bij de ERY gestimuleerde
produktie van PP. Het was echter niet bekend of deze stimulatie van ERY centraal verliep via de
nervus vagus of locaal door gastro-entero-pancreaticogene cholinerge reflexen. Om dit verder te on-
derzoeken werd ERY als een intraveneuze bolus toegediend aan gezonde proefpersonen en aan
patiënten met een accidentele of bewuste vagotomie. De resultaten van deze studie zijn beschreven in
hoofdstuk 4 en laten zien dat het effect van ERY op de produktie van PP voor een belangrijk deel
afhankelijk is van intacte lange nervus vagus takken. De afgenomen produktie van PP na stimulatie
met ERY in patiënten met een vagotomie, neemt verder af indien er ook een antrectomie is verricht.
Dit doet vermoeden dat de produktie van PP door ERY verloopt via de lange vago-vagale takken van
de nervus vagus maar voor een deel ook via de lokale gastro-pancreaticogene cholinerge reflexen.
In de vijftiger- en zestiger jaren kreeg autonome neuropathie meer aandacht. Door clinici en fy-
siologen werden cardiovasculaire reflextesten ontwikkeld en gestandaardiseerd om meer inzage te
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krijgen in het voorkomen van autonome neuropathie. Men nam aan dat deze reflextesten een weer-
spiegeling zouden zijn van een diffuse autonome neuropathie. Inmiddels is gebleken dat schade aan
perifere-, sympathische- en parasympathische zenuwen door autonome neuropathie onafhankelijk
van elkaar kunnen voorkomen. De mate van toename van PP in het bloed na stimulatie van het va-
go-cholinerge systeem, met schijnvoeding of insuline geïnduceerde hypoglycaemie, zou kunnen fun-
geren als parameter voor autonome neuropathie van het maag-darmkanaal. Beide stimuli hebben
echter hun nadelen. Ondanks het feit dat stimulatie van PP door schijnvoeding specifiek is, blijkt
schijnvoeding in de praktijk moeizaam omdat patiënten enerzijds door hun slikreflex kleine hoeveel-
heden voedsel kunnen doorslikken waardoor de test niet meer betrouwbaar is, anderzijds geeft schijn-
voeding slechts een milde stimulatie van de produktie van PP waardoor een vals-positieve uitslag kan
volgen. Bij de door insuline geïnduceerde hypoglycaemie krijgt de patiënt op geleide van zijn
lichaamsgewicht een bolus insuline intraveneus toegediend. Hierdoor probeert men een hypogly-
caemie te verkrijgen van minder dan 2,5 mmol/l waardoor er een zeer sterke vago-cholinerge stim-
ulatie van PP plaatsvindt. Het is met name bij diabetes mellitus patiënten moeilijk, bewerkelijk en
gevaarlijk om de juiste mate van hypoglycaemie te verkrijgen. Stimulatie van de produktie van PP via
het vago-cholinerge systeem door ERY heeft bovenbeschreven nadelen niet.
Om te beoordelen of ERY een rol zou kunnen spelen in het vaststellen van autonome neuropathie
bij patiënten met een chronische leverziekte (hoofdstuk 5) onderzochten we de ERY- (0.4
mg/kg.15min en 1.2 mg/kg.15min) en de schijnvoeding gestimuleerde PP produktie. De resultaten
werden vergeleken met die van patiënten met a-specifieke buikklachten. Het bleek dat de geïnte-
greerde PP-secretie na stimulatie met ERY, maar niet na stimulatie met schijnvoeding, significant was
afgenomen in patiënten met een chronische leverziekte. Bij 4 patiënten met chronisch leverlijden
werden afwijkende cardiovasculaire reflextesten gevonden. De geïntegreerde PP-secretie van deze
patiënten na stimulatie met ERY bleek niet te verschillen van de leverpatiënten met normale cardio-
vasculaire reflextesten.
In hoofdstuk 6 werd de ERY gestimuleerde PP-secretie onderzocht in diabetes mellitus patiënten
met en zonder maag-darmklachten passend bij autonome neuropathie.Alle diabetes mellitus patiën-
ten hadden afwijkende cardiovasculaire reflextesten. De resultaten werden vergeleken met die van
controle patiënten met aspecifieke buikklachten en patiënten met status na vagotomie. De geïnte-
greerde PP-secretie na stimulatie met ERY bleek significant verlaagd bij diabetes mellitus patiënten
met maag-darmklachten passend bij autonome neuropathie en patiënten met een status na vagotomie
in vergelijking met controle patiënten en diabetes mellitus patiënten zonder symptomen.
Om de integriteit van de nervus vagus te onderzoeken bij Parkinson patiënten werd in hoofdstuk
7 de geïntegreerde PP-secretie na stimulatie met insuline geïnduceerde hypoglycaemie onderzocht.
Tevens hielden deze patiënten gedurende een week een klachtendagboek bij en ondergingen zij car-
diovasculaire reflextesten. De resultaten werden vergeleken met die van patiënten met a-typische
buikklachten.De geïntegreerde PP-secretie na insuline geïnduceerde hypoglycaemie bleek bij Parkin-
son patiënten afgenomen in vergelijking met de controles.Verder bleek de geïntegreerde PP-secretie
na insuline geïnduceerde hypoglycaemie significant verlaagd in de Parkinson patiënten met afwij-
kende cardiovasculaire reflex testen en in Parkinson patiënten met maag-darmklachten passend bij
autonome neuropathie in vergelijking met Parkinson patiënten met normale cardiovasculaire reflex
testen en Parkinson patiënten zonder gastro-intestinale klachten.
Op grond van de resultaten beschreven in hoofdstuk 4,5,6 en 7 zou men kunnen veronderstellen
dat de ERY gestimuleerde PP-secretie als een aanvullende test zou kunnen fungeren bij het in kaart
brengen van autonome neuropathie van het maag-darmstelsel.
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Dankwoord
Een oude man uit Aruba vertelde mij, dat een man drie belangrijke dingen in zijn leven zou
moeten doen, namelijk een boom planten, een zoon op de wereld zetten en een boek schrijven.Als
natuurliefhebber had ik met het eerste geen probleem. Inmiddels heb ik, zonder de hulp van anderen,
vele bomen geplant. De tweede proeve was niet gelukt als ik José niet had ontmoet. Inmiddels hebben
we twee schatten van dochters en een stoere zoon op de wereld gezet. Het schrijven van een boekje
was geen sinecure. Het bleek al snel dat dit alleen mogelijk was met de hulp van vele proefpersonen
en de bijdrage van vele medewerkers van diverse afdelingen.
De grondslag van dit proefschrift werd gelegd op de afdeling Gastro-enterologie en hepatologie
van het Academisch Ziekenhuis te Leiden (Prof. Dr. C.B.H.W. Lamers). Nadat ik mijn opleiding tot
gastro-enteroloog was begonnen in het St. Radboud Ziekenhuis te Nijmegen had ik het geluk dat
mijn promotor Prof. Dr. J.B.M.J. Jansen uit Leiden, in Nijmegen tot hoogleraar werd benoemd. Hier-
door was het mogelijk om samen met mijn co-promotor Dr.W.P.M. Hopman het onderzoek te ver-
volgen. Door een vruchtbare samenwerking met de afdeling Interne Geneeskunde (Prof. Dr. Th.
Thien, Dr. P.M. Netten, Dr J.A. Lutterman) en Neurologie (Dr. M.W.I.M. Horstink) werden aanslui-
tend de data voor de hoofdstukken 5, 6 en 7 verzameld.Van de “Maatschap Internisten en Gastro-en-
terologen” van het Gelderse Vallei Ziekenhuis kreeg ik tijd om de verschillende onderzoeksresultaten
op schrift te zetten en af te ronden tot dit proefschrift. Hoewel de bijdragen door alle (proef)personen
verschillend waren en varieërden van wetenschappelijke tot emotionele steun, waren ze allen onmis-
baar.
Daarom wil ik Jan Jansen en bovengenoemde collegae hartelijk danken voor hun belangrijke bij-
drage.Wim Hopman, jij bent niet alleen mijn co-promotor, maar je was ook kamergenoot en buur-
man. Hierdoor was de drempel voor overleg en begeleiding laag en kon ik altijd bij je terecht voor
advies. Bedankt voor je geduld, nauwgezetheid en duidelijkheid. Natuurlijk wil ik de student-assis-
tenten, biochemici, analistes, functielaboratorium-assistentes, diëtisten, verpleegkundigen ook harte-
lijk danken. Zonder anderen tekort te doen wil ik Kim Edwards-Teunissen apart noemen. Kim in-
middels ben je met je eigen onderzoek bezig. Een consciëntieuze en enthousiaste, studente (inmiddels
arts) als jij moet in de toekomst zeker hoge ogen gaan gooien. Bedankt voor alle hulp.
De galblaasmetingen werden door Max Jebbink op de röntgenafdeling van het Leids academisch
medisch centrum en door Wim Hopman op de röntgenafdeling van het St. Radboud ziekenhuis
gedaan. Ik dank beide röntgenafdelingen voor het gebruik van de echokamer met apparatuur.
Verder dank ik Arie en Jan de paranimfen, vrienden, collegae en maten, kennissen, familie, secreta-
resses, endoscopie-assistentes, receptionistes en telefonistes voor hun hulp en begrip.
Beste pa en ma, hartelijk dank voor het vertrouwen dat jullie in mij hebben gesteld en de mo-
gelijkheden die jullie mij hebben geboden.
José, Merel, Marieke en Berend, bedankt voor jullie begrip en steun. Jullie hebben een speciaal
plekje in mijn hart.
Tevens dank ik de voorin het proefschrift genoemde farmaceutische industrieën voor hun finan-
ciële steun.
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Curriculum Vitae
De schrijver van dit proefschrift werd geboren op 16 augustus 1958 te Leiden. In 1974 haalde het
diploma M.A.V.O. en in 1977 het V.W.O.diploma aan het Leeuwenhorst college te Noordwijkerhout.
Aansluitend studeerde hij geneeskunde aan de Rijksuniversiteit te Leiden waar hij in 1983 het doc-
toraal-, en in 1984 het artsexamen aflegde.
Van 1984-1985 werkte hij als vakantie-assistent op de afdeling Gastroenterologie en Hepatologie
van het academisch ziekenhuis te Leiden (AZL). In 1985 begon hij de opleiding tot internist in het
St. Elisabeth ziekenhuis te Leiderdorp (opleider: Dr.W.A. van Amstel). Deze opleiding werd in 1987
voortgezet in het AZL (opleiders: Prof. dr. L.A. van Es en Prof. dr.A.E. Meinders). Na inschrijving in
het specialisten register in Mei 1990 was hij tijdelijk werkzaam op de afdeling Intensive Care (hoofd:
Prof. dr. A.E. Meinders) en de afdeling Maag-, Darm- en Leverziekten (hoofd: Prof. dr. C.B.H.W.
Lamers) van het AZL, waar hij tevens een aanvang maakte met basaal gastro-enterologisch onderzoek,
dat uiteindelijk resulteerde in dit proefschrift.Van september 1991 tot september 1994 was hij werkza-
am op de afdeling Maag-, Darm- en Leverziekten van het St. Radboud ziekenhuis (Opleiders: Prof.
dr. J.H.M. van Tongeren en Prof. dr. J.B.M.J. Jansen). Hier vond tevens de opleiding tot gastro-en-
teroloog plaats en het promotieonderzoek werd afgerond.Vanaf 1 januari 1995 is hij als gastro-en-
teroloog werkzaam in het Gelderse Vallei ziekenhuis te Wageningen.
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